

A-527.ST25.txt
SEQUENCE LISTING

<110> FEIGE, ULRICH
LIU, CHUAN-FA
CHEETHAM, JANET C.
BOONE, THOMAS CHARLES

<120> MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

<130> A-527

<140> 09/428,082

<141> 1999-10-22

<150> 60/105,371

<151> 1998-10-23

<160> 1133

<170> PatentIn version 3.1

<210> 1

<211> 684

<212> DNA

<213> HUMAN

<220>

<221> CDS

<222> (1)..(684)

<223>

<400> 1

atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg	48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu	
1 5 10 15	
ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc	96
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu	
20 25 30	
atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc	144
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser	
35 40 45	
cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag	192
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu	
50 55 60	
gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg	240
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr	
65 70 75 80	
tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat	288
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn	
85 90 95	
ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc	336
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro	
100 105 110	
atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag	384
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln	
115 120 125	
gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc	432
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val	
130 135 140	

A-527.ST25.txt

agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	480
Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	
145					150					155					160	
gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	528
Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	
				165					170					175		
ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	576
Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	
			180					185					190			
gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	624
Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	
		195					200					205				
atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	672
Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	
	210					215					220					
tct	ccg	ggg	aaa													684
Ser	Pro	Gly	Lys													
225																

<210> 2
 <211> 228
 <212> PRT
 <213> HUMAN

<400> 2

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	
1				5					10					15		
Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	
			20					25					30			
Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	
		35					40						45			
His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	
	50					55					60					
Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	
65					70					75					80	
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	
				85					90					95		
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	
			100					105					110			
Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	
		115					120					125				
Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	
	130					135					140					

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys
225

<210> 3
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
<221> misc_feature
<222> (18)..(18)
<223> Methoxy-polyethylene glycol (5000 Dalton)-sulfoacetyl group attached to the sidechain.

<400> 3

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 4
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
<221> misc_feature
<222> (18)..(18)
<223> Methoxy-polyethylene glycol (5000 Dalton)-succinimidyl group attached to the sidechain.

<400> 4

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 5

<211> 794

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<220>

<221> CDS

<222> (39)...(779)

<223>

<400> 5

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
 Met Asp Lys Thr His Thr
 1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
 10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc ggg acc cct 152
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
 25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
 40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
 55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
 75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
 90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
 105 110 115

aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440
 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
 120 125 130

tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488
 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val

A-527.ST25.txt

135		140	145	150	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg					536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly					
		155	160	165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac					584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp					
		170	175	180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg					632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp					
		185	190	195	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac					680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His					
		200	205	210	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga					728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly					
		215	220	225	230
ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt					776
Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg					
		235	240	245	
gct taatctcgag gatcc					794
Ala					

<210> 6
 <211> 247
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-TMP

<400> 6

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu	
1 5 10 15	
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu	
20 25 30	
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser	
35 40 45	
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu	
50 55 60	
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr	
65 70 75 80	
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn	
85 90 95	
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro	
100 105 110	

A-527.ST25.txt

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
225 230 235 240

Gln Trp Leu Ala Ala Arg Ala
245

<210> 7
<211> 861
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP-TMP

<220>
<221> CDS
<222> (39)...(842)
<223>

<400> 7
tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

A-527.ST25.txt

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70
aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Gly Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85
ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
105 110 115
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
120 125 130
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
135 140 145 150
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg 536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
155 160 165
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac 584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
170 175 180
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg 632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
185 190 195
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac 680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
200 205 210
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga 728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly
215 220 225 230
ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 776
Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
235 240 245
gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca acc ctt cgc 824
Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
250 255 260
caa tgg ctt gca gca cgc gcataatctc gaggatccg 861
Gln Trp Leu Ala Ala Arg
265

<210> 8
<211> 268
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc-TMP-TMP

<400> 8

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu

1

5

10

15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
225 230 235 240

Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Ile
245 250 255

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
260 265

<210> 9

```
<220>
<221> CDS
<222> (39) .. (845)
<223>
```

Page 9

```

200          205          210
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 728
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
215          220          225          230

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 776
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
235          240          245

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 824
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
250          255          260

ctc tcc ctg tct ccg ggt aaa taatggatcc 855
Leu Ser Leu Ser Pro Gly Lys
265

<210> 10
<211> 269
<212> PRT
<213> Artificial Sequence

<220>
<223> TMP-TMP-Fc

<400> 10
Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
1          5          10          15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20          25          30

Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
35          40          45

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
50          55          60

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
65          70          75          80

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
85          90          95

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
100         105         110

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
115         120         125

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
130         135         140

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
145         150         155         160

```

A-527.ST25.txt

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
165 170 175

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
180 185 190

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
195 200 205

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
210 215 220

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
225 230 235 240

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
245 250 255

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
260 265

<210> 11
<211> 789
<212> DNA
<213> Artificial Sequence

<220>
<223> TMP-Fc

<220>
<221> CDS
<222> (39)..(779)
<223>

<400> 11
tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56
Met Ile Glu Gly Pro Thr
1 5

ctg cgt cag tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa 104
Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys
10 15 20

act cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg 152
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
25 30 35

tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc 200
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
40 45 50

cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac 248
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
55 60 65 70

cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat 296
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
75 80 85

A-527.ST25.txt

gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg 344
 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
 90 95 100
 gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag 392
 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
 105 110 115
 tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa 440
 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
 120 125 130
 acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc 488
 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
 135 140 145 150
 ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc 536
 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
 155 160 165
 tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag 584
 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
 170 175 180
 agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg 632
 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
 185 190 195
 gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag 680
 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
 200 205 210
 agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag 728
 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
 215 220 225 230
 gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt 776
 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 235 240 245
 aaa taatggatcc 789
 Lys

<210> 12
 <211> 247
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TMP-Fc

<400> 12

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
1 5 10 15

Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
20 25 30

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
35 40 45

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Page 12

50

55

60

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
65 70 75 80

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
85 90 95

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
100 105 110

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
115 120 125

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
130 135 140

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
145 150 155 160

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
165 170 175

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
180 185 190

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
195 200 205

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
210 215 220

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
225 230 235 240

Leu Ser Leu Ser Pro Gly Lys
245

<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> TMP

<400> 13

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 14
<211> 36
<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP

<400> 14

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 15

<211> 812

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-EMP-

<220>

<221> CDS

<222> (39)..(797)

<223>

<400> 15

tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
105 110 115

aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca 440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro

A-527.ST25.txt

120	125	130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc			488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val			
135	140	145	150
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg			536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly			
	155	160	165
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac			584
Gln Pro Glu Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp			
	170	175	180
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg			632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp			
	185	190	195
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac			680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His			
	200	205	210
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga			728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly			
	215	220	225
ggt ggt ggt gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg			776
Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp			
	235	240	245
gtt tgc aaa ccg cag ggt ggt taatctcgtg gatcc			812
Val Cys Lys Pro Gln Gly Gly			
	250		

<210> 16
 <211> 253
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 16

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu	
1	15
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu	
20	30
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser	
35	45
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu	
50	60
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr	
65	80
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn	
85	95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
 245 250

<210> 17
 <211> 807
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EMP-Fc

<220>
 <221> CDS
 <222> (39)..(797)
 <223>

<400> 17
 tctagatttg ttttaactaa ttaaaggagg aataacat atg gga ggt act tac tct 56
 Met Gly Gly Thr Tyr Ser
 1 5

tgc cac ttc ggc ccg ctg act tgg gta tgt aag cca caa ggg ggt ggg 104
 Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 10 15 20

gga ggc ggg ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 152
 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 25 30 35

A-527.ST25.txt

gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 200
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 40 45 50

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 248
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 55 60 65 70

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 296
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 75 80 85

ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 344
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 90 95 100

aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 392
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 105 110 115

tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc 440
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 120 125 130

cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 488
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 135 140 145 150

gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 536
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
 155 160 165

aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 584
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 170 175 180

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 632
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 185 190 195

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 680
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 200 205 210

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 728
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 215 220 225 230

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 776
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 235 240 245

ctc tcc ctg tct ccg ggt aaa taatggatcc 807
 Leu Ser Leu Ser Pro Gly Lys
 250

<210> 18
 <211> 253
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EMP-Fc

<400> 18

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys

1

5

10

15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
20 25 30

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
35 40 45

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
50 55 60

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
65 70 75 80

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
85 90 95

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
100 105 110

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
115 120 125

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
130 135 140

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
145 150 155 160

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
165 170 175

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
210 215 220

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
225 230 235 240

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 19

<211> 881

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<220>

<221> CDS

<222> (41) .. (871)

<223>

<400> 19

tctagatttg agttttaact tttagaagga ggaataaaat atg gga ggt act tac 55
 Met Gly Gly Thr Tyr
 1 5

tct tgc cac ttc ggc cca ctg act tgg gtt tgc aaa ccg cag ggt ggc 103
 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
 10 15 20

ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat ttt ggc ccg ctg acc 151
 Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
 25 30 35

tgg gta tgt aag cca caa ggg ggt ggg gga ggc ggg ggg gac aaa act 199
 Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Asp Lys Thr
 40 45 50

cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca 247
 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 55 60 65

gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 295
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 70 75 80 85

acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct 343
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 90 95 100

gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc 391
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 105 110 115

aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc 439
 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 120 125 130

agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac 487
 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 135 140 145

aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc 535
 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
 150 155 160 165

atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg 583
 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 170 175 180

ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc 631
 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
 185 190 195

ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc 679
 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 200 205 210

aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac 727
 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 Page 19

```

215          220          225
tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc .775
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
230          235          240          245

agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct      823
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
          250          255          260

ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa      871
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
          265          270          275

taatggatcc      881

<210> 20
<211> 277
<212> PRT
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 20

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1          5          10          15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
          20          25          30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly
          35          40          45

Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
          50          55          60

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
          65          70          75          80

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
          85          90          95

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
          100          105          110

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
          115          120          125

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
          130          135          140

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
          145          150          155          160

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

```


165

170

175

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 180 185 190

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 195 200 205

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 210 215 220

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 225 230 235 240

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 245 250 255

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 260 265 270

Leu Ser Pro Gly Lys
 275

<210> 21
 <211> 885
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP-EMP

<220>
 <221> CDS
 <222> (39)..(869)
 <223>

<400> 21
 tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
 Met Asp Lys Thr His Thr
 1 5

tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc 104
 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
 10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
 25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
 40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
 55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val

75

80

85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys	
90 95 100	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser	
105 110 115	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg cct cca	440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro	
120 125 130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	488
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val	
135 140 145 150	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	536
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly	
155 160 165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	584
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp	
170 175 180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	632
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp	
185 190 195	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac	680
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His	
200 205 210	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga	728
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly	
215 220 225 230	
ggt ggt ggc gga ggt act tac tct tgc cac ttc ggc cca ctg act tgg	776
Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp	
235 240 245	
gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc	824
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser	
250 255 260	
tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt	869
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly	
265 270 275	
taatctcgag gatcca	885

<210> 22
 <211> 277
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-EMP-EMP

<400> 22

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 Page 22

20

25

30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
245 250 255

Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
260 265 270

Lys Pro Gln Gly Gly
275

<210> 23

<211> 1546
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> pAMG21

<400> 23
 gcgtaacgta tgcattggtct ccccatgcga gagtagggaa ctgccaggca tcaaataaaa 60
 cgaaaggctc agtcgaaaga ctgggccttt cgttttatct gttgtttgtc ggtgaacgct 120
 ctctgagta ggacaaatcc gccgggagcg gatttgaacg ttgcgaagca acggccccga 180
 ggggtggcggg caggacgcc gccataaact gccaggcatc aaattaagca gaaggccatc 240
 ctgacggatg gcctttttgc gtttctacaa actcttttgt ttatttttct aaatacatc 300
 aaatatggac gtcgtactta acttttaag tatgggcaat caattgctcc tgttaaaatt 360
 gcttttagaaa tactttggca gcggtttgtt gtattgagtt tcatttgccg attggttaaa 420
 tggaaagtga ccgtgcgctt actacagcct aatatttttg aaatatccca agagcttttt 480
 ccttcgcatg cccacgctaa acattctttt tctcttttgg ttaaatcggt gtttgattta 540
 ttatttgcta tattttattt tcgataatta tcaactagag aaggaacaat taatggtatg 600
 ttcatacacg catgtaaaaa taaactatct atatagttgt ctttctctga atgtgcaaaa 660
 ctaagcattc cgaagccatt attagcagta tgaataggga aactaaacc agtgataaga 720
 cctgatgatt tcgcttcttt aattacattt ggagattttt tatttacagc attgttttca 780
 aatatattcc aattaatcgg tgaatgattg gagttagaat aatctactat aggatcatat 840
 tttattaaat tagcgtcatc ataatttgc ctccattttt tagggtaatt atccagaatt 900
 gaaatatcag atttaaccat agaattgagga taaatgatcg cgagtaaata atattcacia 960
 tgtaccattt tagtcatatc agataagcat tgattaatat cattattgct tctacaggct 1020
 ttaattttat taattattct gtaagtgtcg tcggcattta tgtctttcat acccatctct 1080
 ttatccttac ctattgtttg tcgcaagttt tgcgtgttat atatcattaa aacggtaata 1140
 gattgacatt tgattctaata aaattggatt tttgtcacac tattatatcg cttgaaatac 1200
 aattgtttta cataagtacc tgtaggatcg tacaggttta cgcaagaaaa tggtttgta 1260
 tagtcgatta atcgatttga ttctagattt gttttaacta attaaaggag gaataacata 1320
 tgggttaacgc gttggaattc gagctcacta gtgtcgacct gcagggtacc atggaagctt 1380
 actcgaggat ccgcggaaaag aagaagaaga agaagaaagc ccgaaaggaa gctgagttgg 1440
 ctgctgccac cgctgagcaa taactagcat aacccttgg ggcctctaaa cgggtcttga 1500
 ggggtttttt gctgaaagga ggaaccgctc ttcacgctct tcacgc 1546

<210> 24
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 24

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
 1 5 10

<210> 25

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 25

Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 26

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 26

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 27

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 27

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
 1 5 10

<210> 28

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> At position 9 disulfide linkage to position 9 of an identical sequence

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> At position 14, amino acid linker to an identical sequence

<400> 28

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
 1 5 10

<210> 29
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> Position 16 bromoacetyl group linked to sidechain

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> At position 14, amino acid linker attached N-to-C to Lys and to a
 nother linker and an identical sequence

<400> 29

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 30
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> Position 16 polyethylene glycol linked to sidechain

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> At position 14, amino acid linker attached N-to-C to Lys and to a
 nother linker and an identical sequence

<400> 30

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 31

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9 disulfide bond to residue 9 of a separate identical sequence

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 31

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
 1 5 10

<210> 32

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attachment site

<400> 32

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 1 5 10

<210> 33

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (6, 7 and)..(8)

<223> Xaa = any amino acid

<400> 33

Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5

<210> 34
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 34

Thr Leu Arg Glu Trp Leu
1 5

<210> 35
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 35

Gly Arg Val Arg Asp Gln Val Ala Gly Trp
1 5 10

<210> 36
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 36

Gly Arg Val Lys Asp Gln Ile Ala Gln Leu
1 5 10

<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 37

Gly Val Arg Asp Gln Val Ser Trp Ala Leu
1 5 10

<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 38

Glu Ser Val Arg Glu Gln Val Met Lys Tyr
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 39

Ser Val Arg Ser Gln Ile Ser Ala Ser Leu
1 5 10

<210> 40

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 40

Gly Val Arg Glu Thr Val Tyr Arg His Met
1 5 10

<210> 41

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 41

Gly Val Arg Glu Val Ile Val Met His Met Leu
1 5 10

<210> 42

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 42

Gly Arg Val Arg Asp Gln Ile Trp Ala Ala Leu
1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 43

Ala Gly Val Arg Asp Gln Ile Leu Ile Trp Leu
 1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 44

Gly Arg Val Arg Asp Gln Ile Met Leu Ser Leu
 1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(10)

<223> Xaa = any amino acid

<400> 45

Gly Arg Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
 1 5 10

<210> 46

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 46

Cys Thr Leu Arg Gln Trp Leu Gln Gly Cys
 1 5 10

<210> 47

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 47

Cys Thr Leu Gln Glu Phe Leu Glu Gly Cys

1

5

10

<210> 48
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 48

Cys Thr Arg Thr Glu Trp Leu His Gly Cys
 1 5 10

<210> 49
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 49

Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys
 1 5 10

<210> 50
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 50

Cys Thr Leu Arg Glu Trp Val Phe Ala Gly Leu Cys
 1 5 10

<210> 51
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 51

Cys Thr Leu Arg Gln Trp Leu Ile Leu Leu Gly Met Cys
 1 5 10

<210> 52
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 52

Cys Thr Leu Ala Glu Phe Leu Ala Ser Gly Val Glu Gln Cys
 1 5 10

<210> 53
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 53

Cys Ser Leu Gln Glu Phe Leu Ser His Gly Gly Tyr Val Cys
 1 5 10

<210> 54
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 54

Cys Thr Leu Arg Glu Phe Leu Asp Pro Thr Thr Ala Val Cys
 1 5 10

<210> 55
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 55

Cys Thr Leu Lys Glu Trp Leu Val Ser His Glu Val Trp Cys
 1 5 10

<210> 56
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(9)
 <223> Xaa = any amino acid

<400> 56

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
 1 5 10

<210> 57

<211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(10)
 <223> Xaa = any amino acid

<400> 57

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Cys
 1 5 10

<210> 58
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(11)
 <223> Xaa = any amino acid

<400> 58

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Cys
 1 5 10

<210> 59
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(12)
 <223> Xaa = any amino acid

<400> 59

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys
 1 5 10

<210> 60
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature
 <222> (8)..(13)
 <223> Xaa = any amino acid

<400> 60

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa Cys
 1 5 10

<210> 61
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 61

Arg Glu Gly Pro Thr Leu Arg Gln Trp Met
 1 5 10

<210> 62
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 62

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
 1 5 10

<210> 63
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 63

Glu Arg Gly Pro Phe Trp Ala Lys Ala Cys
 1 5 10

<210> 64
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 64

Arg Glu Gly Pro Arg Cys Val Met Trp Met
 1 5 10

<210> 65

<211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 65

Cys Gly Thr Glu Gly Pro Thr Leu Ser Thr Trp Leu Asp Cys
 1 5 10

<210> 66
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 66

Cys Glu Gln Asp Gly Pro Thr Leu Leu Glu Trp Leu Lys Cys
 1 5 10

<210> 67
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 67

Cys Glu Leu Val Gly Pro Ser Leu Met Ser Trp Leu Thr Cys
 1 5 10

<210> 68
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 68

Cys Leu Thr Gly Pro Phe Val Thr Gln Trp Leu Tyr Glu Cys
 1 5 10

<210> 69
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 69

Cys Arg Ala Gly Pro Thr Leu Leu Glu Trp Leu Thr Leu Cys
 1 5 10

<210> 70
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 70

Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
 1 5 10

<210> 71
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2)..(12)
 <223> Xaa = any amino acid

<400> 71

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
 1 5 10

<210> 72
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 3)..(13)
 <223> Xaa = any amino acid

<400> 72

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
 1 5 10

<210> 73
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 12)..(13)
 <223> Xaa = any amino acid

<400> 73

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
 1 5 10

<210> 74

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 13)..(14)

<223> Xaa = any amino acid

<400> 74

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
 1 5 10 15

<210> 75

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 75

Gly Gly Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys Gly Gly
 1 5 10 15

<210> 76

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 76

Gly Gly Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
 1 5 10 15

Gly Gly

<210> 77

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 77

Gly Asn Ala Asp Gly Pro Thr Leu Arg Gln Trp Leu Glu Gly Arg Arg
1 5 10 15

Pro Lys Asn -

<210> 78
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 78

Leu Ala Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu His Gly Asn Gly
1 5 10 15

Arg Asp Thr

<210> 79
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 79

His Gly Arg Val Gly Pro Thr Leu Arg Glu Trp Lys Thr Gln Val Ala
1 5 10 15

Thr Lys Lys

<210> 80
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDE

<400> 80

Thr Ile Lys Gly Pro Thr Leu Arg Gln Trp Leu Lys Ser Arg Glu His
1 5 10 15

Thr Ser

<210> 81
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE
 <400> 81

Ile Ser Asp Gly Pro Thr Leu Lys Glu Trp Leu Ser Val Thr Arg Gly
 1 5 10 15

Ala Ser

<210> 82
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO MIMETIC PEPTIDE
 <400> 82

Ser Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Thr Ser Arg Thr Pro
 1 5 10 15

His Ser

<210> 83
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 4, 5, 8, 11)..(13)
 <223> Xaa = any amino acid

<400> 83

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 84
 <211> 28
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 4, 5, 8, 11, 13, 16, 18, 19, 22, 25)..(27)
 <223> Xaa = any amino acid

<400> 84

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Tyr Xaa
 Page 39

1

5

10

15

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 20 25

<210> 85
 <211> 14
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> EPO-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (14)..(14)
 <223> At position 14, amino acid linker to an identical sequence

<220>
 <221> misc_feature
 <222> (2, 4, 5, 8, 11)..(13)
 <223> Xaa = any amino acid

<400> 85

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 86
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 4, 5, 8, 11)..(13)
 <223> Xaa = any amino acid

<400> 86

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
 1 5 10

<210> 87
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 87

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly

20

<210> 88
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 88

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Leu Gly Gly
 20

<210> 89
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 89

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
 1 5 10 15

Pro Leu Gly Gly
 20

<210> 90
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 90

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly Gly
 20

<210> 91
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 91

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
 Page 41

1 5 10 15

Tyr Lys Gly Gly
20

<210> 92
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<400> 92

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
20 25 30

Trp Val Cys Lys Pro Gln Gly Gly
35 40

<210> 93
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (20)..(20)
<223> Position 20, amino acid linker to an identical sequence

<400> 93

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20

<210> 94
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<400> 94

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys

20

<210> 95
 <211> 46
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 95

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Ser Ser Lys Gly Gly Thr Tyr Ser Cys His Phe Gly
 20 25 30

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys
 35 40 45

<210> 96
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> Position 23, amino acid linker to an identical sequence

<400> 96

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
 20

<210> 97
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> Position 22 linked through epsilon amine to lysyl, which is linked to a separate identical sequence through that sequence's alpha amine

<400> 97

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 Page 43

1 5 15

Pro Gln Gly Gly Ser Ser
20

<210> 98
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (23)..(23)
<223> At position 23 biotin linked to the sidechain through a linker

<400> 98

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 99
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (4)..(4)
<223> At position 4 disulfide bond to residue 4 of a separate identical sequence

<400> 99

Glu Glu Asp Cys Lys
1 5

<210> 100
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (4)..(4)
<223> At position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence

<400> 100

Glu Glu Asp Xaa Lys
1 5

<210> 101 -
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is a pyroglutamic acid residue

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 101

Xaa Gly Glu Asp Xaa Lys
1 5

<210> 102
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is a picolinic acid residue

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 102

Xaa Ser Asp Xaa Lys
1 5

<210> 103
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature
 <222> (5)..(5)
 <223> At position 5, amino acid linker to an identical sequence

<400> 103

Glu Glu Asp Cys Lys
 1 5

<210> 104
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> G-CSF-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> At position 5, amino acid linker to an identical sequence

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Xaa = any amino acid

<400> 104

Glu Glu Asp Xaa Lys
 1 5

<210> 105
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIVIRAL (HBV)

<400> 105

Leu Leu Gly Arg Met Lys
 1 5

<210> 106
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 106

Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr
 1 5 10

<210> 107
 <211> 11
 <212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 107 -

Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr
1 5 10

<210> 108

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 108

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr
1 5 10

<210> 109

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 109

Phe Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 110

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 110

Tyr Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 111

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 111

Phe Cys Asn Ser Glu Asn His Cys Tyr
1 5

<210> 112

<211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 112

Phe Cys Asn Ser Glu Asn Arg Cys Tyr
 1 5

<210> 113
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 113

Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr
 1 5 10

<210> 114
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 114

Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe
 1 5 10

<210> 115
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 115

Phe Cys Val Ser Asn Asp Arg Cys Tyr
 1 5

<210> 116
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TNF ANTAGONIST PEPTIDE

<400> 116

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr
 1 5 10

<210> 117
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 117

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr
1 5

<210> 118
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 118

Tyr Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 119
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 119

Phe Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 120
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 120

Tyr Cys Trp Ser Gln Asn Leu Cys Tyr
1 5

<210> 121
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 121

Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr
Page 49

1 5

<210> 122
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 122

Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr
1 5

<210> 123
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> TNF ANTAGONIST PEPTIDE

<400> 123

Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr
1 5

<210> 124
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa (Pos1) can be C, A, a-amino-g-bromobutyric acid or Hoc.

<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa can be R, H, L or W.

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be M, F or I.

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa can be any one of the 20 L-amino acids or the stereoisomeric D-amino acids.

<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa can be D, E, I, L or V.

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Xaa can-be a-amino-g-bromobutyric acid or Hoc, provided that either Xaa (Pos1) or Xaa (Pos10) is C or Hoc.

<400> 124

Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
 1 5 10

<210> 125
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CTLA4-MIMETIC

<400> 125

Gly Phe Val Cys Ser Gly Ile Phe Ala Val Gly Val Gly Arg Cys
 1 5 10 15

<210> 126
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CTLA4-MIMETIC

<400> 126

Ala Pro Gly Val Arg Leu Gly Cys Ala Val Leu Gly Arg Tyr Cys
 1 5 10 15

<210> 127
 <211> 27
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> C3B ANTAGONIST

<400> 127

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr Ala Gly His
 1 5 10 15

Met Ala Asn Leu Thr Ser His Ala Ser Ala Ile
 20 25

<210> 128
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> C3B ANTAGONIST

<400> 128

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr
 1 5 10

<210> 129

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 129

Cys Val Val Gln Asp Trp Gly His His Ala Cys
 1 5 10

<210> 130

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 130

Thr Phe Ser Asp Leu Trp
 1 5

<210> 131

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 131

Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
 1 5 10

<210> 132

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 132

Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
 1 5 10

<210> 133

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 133

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
 1 5 10

<210> 134

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 134

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
 1 5 10

<210> 135

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 135

Met Pro Arg Phe Met Asp Tyr Trp Glu Gly Leu Asn
 1 5 10

<210> 136

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 136

Val Gln Asn Phe Ile Asp Tyr Trp Thr Gln Gln Phe
 1 5 10

<210> 137

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 137

Thr Gly Pro Ala Phe Thr His Tyr Trp Ala Thr Phe
 1 5 10

<210> 138

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 138

Ile Asp Arg Ala Pro Thr Phe Arg Asp His Trp Phe Ala Leu Val
1 5 10 15

<210> 139

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 139

Pro Arg Pro Ala Leu Val Phe Ala Asp Tyr Trp Glu Thr Leu Tyr
1 5 10 15

<210> 140

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 140

Pro Ala Phe Ser Arg Phe Trp Ser Asp Leu Ser Ala Gly Ala His
1 5 10 15

<210> 141

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 141

Pro Ala Phe Ser Arg Phe Trp Ser Lys Leu Ser Ala Gly Ala His
1 5 10 15

<210> 142

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 8)..(9)

<223> Xaa = any amino acid

<400> 142

Pro Xaa Phe Xaa Asp Tyr Trp Xaa Xaa Leu
 1 5 10

<210> 143
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 143

Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
 1 5 10

<210> 144
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 144

Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
 1 5 10

<210> 145
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 145

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
 1 5 10

<210> 146
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MDM/HDM ANTAGONIST PEPTIDE

<400> 146

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
 1 5 10

<210> 147
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<400> 147

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 148

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 148

Asp Ile Thr Trp Asp Glu Leu Trp Lys Ile Met Asn
 1 5 10

<210> 149

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 149

Asp Tyr Thr Trp Phe Glu Leu Trp Asp Met Met Gln
 1 5 10

<210> 150

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 150

Gln Ile Thr Trp Ala Gln Leu Trp Asn Met Met Lys
 1 5 10

<210> 151

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 151

Asp Met Thr Trp His Asp Leu Trp Thr Leu Met Ser
 1 5 10

<210> 152

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 152

Asp Tyr Ser Trp His Asp Leu Trp Glu Met Met Ser
 1 5 10

<210> 153

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 153

Glu Ile Thr Trp Asp Gln Leu Trp Glu Val Met Asn
 1 5 10

<210> 154

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 154

His Val Ser Trp Glu Gln Leu Trp Asp Ile Met Asn
 1 5 10

<210> 155

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 155

His Ile Thr Trp Asp Gln Leu Trp Arg Ile Met Thr
 1 5 10

<210> 156

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 156

Arg Asn Met Ser Trp Leu Glu Leu Trp Glu His Met Lys
 1 5 10

<210> 157

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 157 -

Ala Glu Trp Thr Trp Asp Gln Leu Trp His Val Met Asn Pro Ala Glu
1 5 10 15

Ser Gln

<210> 158

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 158

His Arg Ala Glu Trp Leu Ala Leu Trp Glu Gln Met Ser Pro
1 5 10

<210> 159

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 159

Lys Lys Glu Asp Trp Leu Ala Leu Trp Arg Ile Met Ser Val
1 5 10

<210> 160

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 160

Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 161

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 161

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
Page 58

1

5

10

<210> 162
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<400> 162

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 163
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<400> 163

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 164
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 164

Ser Cys Val Lys Trp Gly Lys Lys Glu Phe Cys Gly Ser
 1 5 10

<210> 165
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 165

Ser Cys Trp Lys Tyr Trp Gly Lys Glu Cys Gly Ser
 1 5 10

<210> 166
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 166

Ser Cys Tyr Glu Trp Gly Lys Leu Arg Trp Cys Gly Ser
1 5 10

<210> 167
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 167

Ser Cys Leu Arg Trp Gly Lys Trp Ser Asn Cys Gly Ser
1 5 10

<210> 168
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 168

Ser Cys Trp Arg Trp Gly Lys Tyr Gln Ile Cys Gly Ser
1 5 10

<210> 169
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 169

Ser Cys Val Ser Trp Gly Ala Leu Lys Leu Cys Gly Ser
1 5 10

<210> 170
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 170

Ser Cys Ile Arg Trp Gly Gln Asn Thr Phe Cys Gly Ser
1 5 10

<210> 171
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 171

Ser Cys Trp Gln Trp Gly Asn Leu Lys Ile Cys Gly Ser
1 5 10

<210> 172

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 172

Ser Cys Val Arg Trp Gly Gln Leu Ser Ile Cys Gly Ser
1 5 10

<210> 173

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 173

Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr
1 5 10 15

Thr Met Leu Ala Lys
20

<210> 174

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 174

Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg Phe
1 5 10 15

Lys Lys

<210> 175

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 175

Arg Lys Trp Gln Lys Thr Gly His Ala Val Arg Ala Ile Gly Arg Leu

1

5

10

15

Ser Ser

<210> 176
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 176

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
 1 5 10

<210> 177
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 177

Lys Ile Trp Ser Ile Leu Ala Pro Leu Gly Thr Thr Leu Val Lys Leu
 1 5 10 15

Val Ala

<210> 178
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 178

Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu
 1 5 10

<210> 179
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 179

Leu Lys Trp Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys
 1 5 10 15

Leu Leu

<210> 180
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 180

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys Thr Leu Ser His Phe Ser
 1 5 10 15

Val

<210> 181
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 181

Ala Glu Trp Pro Ser Pro Thr Arg Val Ile Ser Thr Thr Tyr Phe Gly
 1 5 10 15

Ser

<210> 182
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 182

Ala Glu Leu Ala His Trp Pro Pro Val Lys Thr Val Leu Arg Ser Phe
 1 5 10 15

Thr

<210> 183
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CALMODULIN ANTAGONIST PEPTIDE

<400> 183

Ala Glu Gly Ser Trp Leu Gln Leu Leu Asn Leu Met Lys Gln Met Asn
 Page 63

1

5

10

15

Asn

<210> 184
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 184

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys
1 5 10

<210> 185
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> VINCULIN-BINDING

<400> 185

Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Gly Val Ser
1 5 10 15

Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
20 25

<210> 186
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> VINCULIN-BINDING

<400> 186

Ser Thr Gly Gly Phe Asp Asp Val Tyr Asp Trp Ala Arg Arg Val Ser
1 5 10 15

Ser Ala Leu Thr Thr Thr Leu Val Ala Thr Arg
20 25

<210> 187
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VINCULIN-BINDING

<400> 187

Ser Arg Gly Val Asn Phe Ser Glu Trp Leu Tyr Asp Met Ser Ala Ala
Page 64

1 5 10 15

Met Lys Glu Ala Ser Asn Val Phe Pro Ser Arg Arg Ser Arg
 20 25 30

<210> 188
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VINCULIN-BINDING

<400> 188

Ser Ser Gln Asn Trp Asp Met Glu Ala Gly Val Glu Asp Leu Thr Ala
 1 5 10 15

Ala Met Leu Gly Leu Leu Ser Thr Ile His Ser Ser Ser Arg
 20 25 30

<210> 189
 <211> 31
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VINCULIN-BINDING

<400> 189

Ser Ser Pro Ser Leu Tyr Thr Gln Phe Leu Val Asn Tyr Glu Ser Ala
 1 5 10 15

Ala Thr Arg Ile Gln Asp Leu Leu Ile Ala Ser Arg Pro Ser Arg
 20 25 30

<210> 190
 <211> 31
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VINCULIN-BINDING

<400> 190

Ser Ser Thr Gly Trp Val Asp Leu Leu Gly Ala Leu Gln Arg Ala Ala
 1 5 10 15

Asp Ala Thr Arg Thr Ser Ile Pro Pro Ser Leu Gln Asn Ser Arg
 20 25 30

<210> 191
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VINCULIN-BINDING

<400> 191

Asp Val Tyr Thr Lys Lys Glu Leu Ile Glu Cys Ala Arg Arg Val Ser
 1 5 10 15

Glu Lys

<210> 192

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 192

Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile
 1 5 10 15

Asp Tyr Asn Asn Val Ser
 20

<210> 193

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 193

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala
 1 5 10 15

Glu Gly Trp His Val Asn
 20

<210> 194

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 194

Leu Val Thr Val Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala
 1 5 10 15

Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His
 20 25 30

Val Asn

<210> 195
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> C4BP-BINDING

<400> 195

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser
 1 5 10

<210> 196
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 196

Ala Glu Pro Met Pro His Ser Leu Asn Phe Ser Gln Tyr Leu Trp Tyr
 1 5 10 15

Thr

<210> 197
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 197

Ala Glu His Thr Tyr Ser Ser Leu Trp Asp Thr Tyr Ser Pro Leu Ala
 1 5 10 15

Phe

<210> 198
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 198

Ala Glu Leu Asp Leu Trp Met Arg His Tyr Pro Leu Ser Phe Ser Asn
 1 5 10 15

Arg

<210> 199
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 199

Ala Glu Ser Ser Leu Trp Thr Arg Tyr Ala Trp Pro Ser Met Pro Ser
 1 5 10 15

Tyr

<210> 200
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 200

Ala Glu Trp His Pro Gly Leu Ser Phe Gly Ser Tyr Leu Trp Ser Lys
 1 5 10 15

Thr

<210> 201
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 201

Ala Glu Pro Ala Leu Leu Asn Trp Ser Phe Phe Phe Asn Pro Gly Leu
 1 5 10 15

His

<210> 202
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 202

Ala Glu Trp Ser Phe Tyr Asn Leu His Leu Pro Glu Pro Gln Thr Ile
 1 5 10 15

Phe

<210> 203 -
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 203

Ala Glu Pro Leu Asp Leu Trp Ser Leu Tyr Ser Leu Pro Pro Leu Ala
 1 5 10 15

Met

<210> 204
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 204

Ala Glu Pro Thr Leu Trp Gln Leu Tyr Gln Phe Pro Leu Arg Leu Ser
 1 5 10 15

Gly

<210> 205
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 205

Ala Glu Ile Ser Phe Ser Glu Leu Met Trp Leu Arg Ser Thr Pro Ala
 1 5 10 15

Phe

<210> 206
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 206

A-527.ST25.txt

Ala Glu Leu Ser Glu Ala Asp Leu Trp Thr Thr Trp Phe Gly Met Gly
1 5 10 15

Ser

<210> 207
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 207

Ala Glu Ser Ser Leu Trp Arg Ile Phe Ser Pro Ser Ala Leu Met Met
1 5 10 15

Ser

<210> 208
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 208

Ala Glu Ser Leu Pro Thr Leu Thr Ser Ile Leu Trp Gly Lys Glu Ser
1 5 10 15

Val

<210> 209
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 209

Ala Glu Thr Leu Phe Met Asp Leu Trp His Asp Lys His Ile Leu Leu
1 5 10 15

Thr

<210> 210
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE
 <400> 210

Ala Glu Ile Leu Asn Phe Pro Leu Trp His Glu Pro Leu Trp Ser Thr
 1 5 10 15

Glu

<210> 211
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE
 <400> 211

Ala Glu Ser Gln Thr Gly Thr Leu Asn Thr Leu Phe Trp Asn Thr Leu
 1 5 10 15

Arg

<210> 212
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Xaa is V, L, I, E, P, G, Y, M, T or D.

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Xaa is Y, W or F.

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Xaa is F, W or Y.

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa is P or Azetidine.

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Xaa is S, A, V or L.

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Xaa is V, L, I or E.

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> Xaa is Q or P.

<400> 212

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 213
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 213

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 214
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 214

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu

<210> 215
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 215

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 216
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 216

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 217
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 217

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 218
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 218

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 219
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 219

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
 1 5 10

<210> 220
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 220

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
 1 5 10

<210> 221
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 221

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 222
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, optionally acetlated at N terminus

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 222

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 223
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = azetidine

<400> 223

Phe Glu Trp Thr Pro Gly Trp Pro Tyr Gln Xaa Tyr
1 5 10

<210> 224

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 224

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 225

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 225

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 226

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 226

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 227

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 227

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 228

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, optionally acetylated at N terminus

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 228

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 229

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa products = "MeGly"

<220>

<221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 229 -

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 230
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa = MeGly

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 230

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 231
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 231

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
 1 5 10

<210> 232
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 232

Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
 1 5 10

<210> 233
 <211> 11
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 233

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 234

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 234

Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 235

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 235

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 236

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = Aib

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 236

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
1 5 10

<210> 237

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = MeGly

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 237

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 238

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, amino group added at C terminus

<400> 238

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
Page 79

1

5

10

<210> 239
 <211> 11
 <212> PRT -
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11, amino group added at C-terminus

<400> 239

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
 1 5 10

<210> 240
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue
 Position 11 amino group added at C-terminus

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 240

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 241
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 optionally acetylated at N-terminus

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 241

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 242
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Position 8, Xaa is a phyosphotyrosyl residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 242

Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr
 1 5 10

<210> 243
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 243

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 244
 <211> 11 -
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 244

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 245
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 245

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 246
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 246

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 247
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 acetylated at N-terminus

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 247

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 248
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, D amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature

<222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 248

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 249
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is a sarcosine residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 249

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 250
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 250

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
 1 5 10

<210> 251
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 251

Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
 1 5 10

<210> 252
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 252

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
 1 5 10

<210> 253
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, D amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 253

Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 254
 <211> 11

<212> PRT
 <213> Artificial Sequence
 <220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa is a pipecolic acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 254

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 255
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa = pipecolic acid

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 255

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 256
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = MeGly

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position: 10, Xaa = azetidine

<400> 256

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 257
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 257

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 258
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is a 1-naphthylalanine residue

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<220>
<221> misc_feature
<222> (11)..(11)
<223> Position 11 amino group added at C-terminus

<400> 258

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 259
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

 <400> 259

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 260
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 260

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 261
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, D amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 261

Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 262
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, D amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 262

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 263
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 263

Thr Lys Pro Arg
 1

<210> 264
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 264

Arg Lys Ser Ser Lys
 1 5

<210> 265
 <211> 5
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 265

Arg Lys Gln Asp Lys
1 5

<210> 266

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 266

Asn Arg Lys Gln Asp Lys
1 5

<210> 267

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 267

Arg Lys Gln Asp Lys Arg
1 5

<210> 268

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 268

Glu Asn Arg Lys Gln Asp Lys Arg Phe
1 5

<210> 269

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 269

Val Thr Lys Phe Tyr Phe
1 5

<210> 270

<211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 270

Val Thr Lys Phe Tyr
 1 5

<210> 271
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 271

Val Thr Asp Phe Tyr
 1 5

<210> 272
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE
 <400> 272

Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr
 1 5 10 15

Arg

<210> 273
 <211> 17
 <212> PRT
 <213> Artificial SEquence

<220>
 <223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE
 <400> 273

Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg
 1 5 10 15

Thr

<210> 274
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 274

Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His
 1 5 10 15

Pro Met Ser Ser
 20

<210> 275

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 275

Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His
 1 5 10 15

Pro Met Ser Ser
 20

<210> 276

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 276

Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His
 1 5 10 15

Trp Ser Met Ala
 20

<210> 277

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 277

Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His
 1 5 10 15

Trp Ser Met Ala
 20

<210> 278

<211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE
 <400> 278

Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser
 1 5 10 15

Ala Lys His Gly
 20

<210> 279
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTI-HBV
 <400> 279

Leu Leu Gly Arg Met Lys
 1 5

<210> 280
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTI-HBV
 <400> 280

Ala Leu Leu Gly Arg Met Lys Gly
 1 5

<210> 281
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTI-HBV
 <400> 281

Leu Asp Pro Ala Phe Arg
 1 5

<210> 282
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 282

Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 283 -
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<400> 283

Arg Glu Leu Pro Pro Leu Pro
1 5

<210> 284
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<400> 284

Ser Pro Leu Pro Pro Leu Pro
1 5

<210> 285
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<400> 285

Gly Pro Leu Pro Pro Leu Pro
1 5

<210> 286
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<400> 286

Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 287
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<400> 287

Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 288

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 288

Arg Arg Leu Pro Pro Thr Pro
1 5

<210> 289

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 289

Arg Gln Leu Pro Pro Thr Pro
1 5

<210> 290

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 290

Arg Pro Leu Pro Ser Arg Pro
1 5

<210> 291

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 291

Arg Pro Leu Pro Thr Arg Pro
1 5

<210> 292

<211> 7

<212> PRT

<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE
<400> 292

Ser Arg Leu Pro Pro Leu Pro
1 5

<210> 293
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE
<400> 293

Arg Ala Leu Pro Ser Pro Pro
1 5

<210> 294
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE
<400> 294

Arg Arg Leu Pro Arg Thr Pro
1 5

<210> 295
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE
<400> 295

Arg Pro Val Pro Pro Ile Thr
1 5

<210> 296
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE
<400> 296

Ile Leu Ala Pro Pro Val Pro
1 5

<210> 297
<211> 7
<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 297 -

Arg Pro Leu Pro Met Leu Pro
1 5

<210> 298

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 298

Arg Pro Leu Pro Ile Leu Pro
1 5

<210> 299

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 299

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 300

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 300

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 301

Arg Pro Leu Pro Met Ile Pro
1 5

<210> 302

<211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<400> 302

Arg Pro Leu Pro Leu Ile Pro
 1 5

<210> 303
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<400> 303

Arg Pro Leu Pro Pro Thr Pro
 1 5

<210> 304
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<400> 304

Arg Ser Leu Pro Pro Leu Pro
 1 5

<210> 305
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<400> 305

Arg Pro Gln Pro Pro Pro Pro
 1 5

<210> 306
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<400> 306

Arg Gln Leu Pro Ile Pro Pro
 1 5

<210> 307
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 2, 3)..(11)
 <223> Xaa = any amino acid

<400> 307

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
 1 5 10

<210> 308
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 2, 3, 11)..(12)
 <223> Xaa = any amino acid

<400> 308

Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa
 1 5 10

<210> 309
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 2, 3, 11,)..(12)
 <223> Xaa = any amino acid

<400> 309

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa
 1 5 10

<210> 310
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (2, 3, 10)..(11)
<223> Xaa = any amino acid

<400> 310

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
1 5 10

<210> 311
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (2)..(3)
<223> Xaa = any amino acid

<400> 311

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Pro Pro
1 5 10

<210> 312
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa = any amino acid

<400> 312

Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 313
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> SH3 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa = any amino acid

<400> 313

Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa
 1 5 10

<210> 314 -
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 3)..(8)
 <223> Xaa (Pos2, 3, 8) is any amino acid

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> Xaa (Pos 9) represents an aliphatic amino acid residue

<400> 314

Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro
 1 5 10

<210> 315
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is an aliphatic amino acid residue

<220>
 <221> misc_feature
 <222> (2, 3)..(8)
 <223> Positions 2, 3 & 8, Xaa is any amino acid

<400> 315

Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro ..
 1 5 10

<210> 316
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature

<222> (3)..(3)
 <223> Position 3, Xaa is any amino acid residue

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Position 4, Xaa is an aromatic amino acid residue

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> Position 9, Xaa is an aliphatic amino acid residue

<400> 316

Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro
 1 5 10

<210> 317
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a basic amino acid residue

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Position 4, Xaa is an aliphatic amino acid residue

<220>
 <221> misc_feature
 <222> (6)..(9)
 <223> Positions 6 & 9, Xaa is any amino acid residue

<400> 317

Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu
 1 5 10

<210> 318
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (3, 4)..(6)
 <223> Positions 3, 4 & 6, Xaa is an aliphatic amino acid residue

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Position 8, Xaa is a basic amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is any amino acid residue

<400> 318

Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro
 1 5 10

<210> 319
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(9)
 <223> Xaa = any amino acid

<400> 319

Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu
 1 5 10

<210> 320
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 3)..(6)
 <223> Positions 1, 3 and 6, Xaa is an aliphatic amino acid residue

<400> 320

Xaa Pro Xaa Leu Pro Xaa Lys
 1 5

<210> 321
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a basic amino acid residue

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is an aromatic amino acid residue

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> Positions 4 & 8, Xaa is any amino acid residue

<400> 321

Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro
 1 5 10

<210> 322
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INHIBITION OF PLATELET AGGREGATION

<220>
 <221> misc_feature
 <222> (2)..(3)
 <223> Xaa = any amino acid

<400> 322

Cys Xaa Xaa Arg Gly Asp Cys
 1 5

<210> 323
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SRC ANTAGONIST

<400> 323

Arg Pro Leu Pro Pro Leu Pro
 1 5

<210> 324
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SRC ANTAGONIST

<400> 324

Pro Pro Val Pro Pro Arg
1 5

<210> 325
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTI-CANCER (PARTICULARLY FOR SARCOMAS)

<220>
<221> misc_feature
<222> (1, 3, 5, 7, 8, 10)..(11)
<223> Xaa = any amino acid

<400> 325

Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa
1 5 10

<210> 326
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> P16-MIMETIC

<400> 326

Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

<210> 327
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> P16-MIMETIC

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
1 5 10 15

Asp Phe Ala Trp
20

<210> 328
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 328

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
 1 5 10 15

Leu Ile Phe Ser
 20

<210> 329

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 329

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
 1 5 10 15

Lys Arg Lys Pro
 20

<210> 330

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 330

Arg Arg Leu Ile Phe
 1 5

<210> 331

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 331

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
 1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
 20 25 30

Lys Trp Lys Lys
 35

<210> 332

<211> 24

<212> PRT
<213> Artificial Sequence

<220>
<223> P16-MIMETIC

<400> 332

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
1 5 10 15

Asn Arg Arg Met Lys Trp Lys Lys
20

<210> 333
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> PREFERRED LINKER

<400> 333

Gly Gly Gly Lys Gly Gly Gly Gly
1 5

<210> 334
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> PREFERRED LINKER

<400> 334

Gly Gly Gly Asn Gly Ser Gly Gly
1 5

<210> 335
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> PREFERRED LINKER

<400> 335

Gly Gly Gly Cys Gly Gly Gly Gly
1 5

<210> 336
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> PREFERRED LINKER

<400> 336

Gly Pro Asn Gly Gly
1 5

<210> 337
<211> 41
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC

<220>
<221> misc_feature
<222> (1)..(1)
<223> Fc domain attached at Position 1 of the N-terminus

<400> 337

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15

Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr
20 25 30

Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 338
<211> 41
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC

<220>
<221> misc_feature
<222> (41)..(41)
<223> Fc domain attached at Position 41 of the C-terminus

<400> 338

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly
35 40

<210> 339
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus

<400> 339

Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu
 1 5 10 15

Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr
 20 25 30

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly
 35 40 45

Gly

<210> 340
 <211> 49
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC

<220>
 <221> misc_feature
 <222> (49)..(49)
 <223> Fc domain attached at Position 49 of the C-terminus

<400> 340

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe
 20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly
 35 40 45

Gly

<210> 341
 <211> 28
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 341

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu
 1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 342
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 342

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 343
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 343

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 344
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 344

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 345
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 345

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 20 25 30

<210> 346

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 346

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 20 25 30

Ala

<210> 347

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 347

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
 20 25 30

Arg Ala

<210> 348

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 348

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
 20 25 30

Ala Arg Ala
 35

<210> 349
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 349

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 350
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 350

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala
 35

<210> 351
 <211> 38
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 351

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln
 20 25 30

Trp Leu Ala Ala Arg Ala
35

<210> 352
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 352

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 353
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 353

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 354
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC PEPTIDES

<400> 354

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 355
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 355

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 356
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 356

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 357
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 357

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 358
 <211> 37

<212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> Position 19, Xaa = bromoacetyl

<400> 358

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala
 35

<210> 359
 <211> 36
 <212> PRT
 <213> Artificial Sequence

...<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 359

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 360
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> Position 19, Xaa = Poly(ethylene glycol)

<400> 360

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala
 35

<210> 361
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> Position 19, Xaa = Poly(ethylene glycol)

<400> 361

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Cys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala
 35

<210> 362
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 362

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 363
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDES

<400> 363

A-527.ST25.txt

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20- 25 30

Ala Ala Arg Ala
35

<210> 364
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 364
aaaaaaggat cctcgagatt aagcacgagc agccagccac tgacgcagag tcggacc 57

<210> 365
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 365
aaaggtggag gtggtggtat cgaaggtccg actctgcgt 39

<210> 366
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 366
cagtggctgg ctgctcgtgc ttaatctcga ggatcctttt tt 42

<210> 367
<211> 81
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<220>
<221> CDS
<222> (1)..(60)
<223>

<400> 367
aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

gct gct cgt gct taatctcgag gatccttttt t 81

Ala Ala Arg Ala
20

<210> 368
<211> 20 -
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 368

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala
20

<210> 369
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 369
aacataagta cctgtaggat cg

22

<210> 370
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP

<400> 370
ttcgatacca ccacctccac ctttaccgag agacagggag aggctcttct gc

52

<210> 371
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP-TMP

<400> 371
aaagggtggag gtggtggtat cgaagggtccg actctgcgtc agtggctggc tgctcgtgct

60

<210> 372
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-TMP-TMP

<400> 372
acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc

48

<210> 373
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 373
 ggtggtggag gtggcgggcgg aggtattgag ggcccaaccc ttcgccaatg gcttgcagca 60
 cgcgca 66

<210> 374
 <211> 76
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 374
 Ala Ala Ala Ala Ala Ala Ala Gly Gly Ala Thr Cys Cys Thr Cys Gly
 1 5 10 15
 Ala Gly Ala Thr Thr Ala Thr Gly Cys Gly Cys Gly Thr Gly Cys Thr
 20 25 30
 Gly Cys Ala Ala Gly Cys Cys Ala Thr Thr Gly Gly Cys Gly Ala Ala
 35 40 45
 Gly Gly Gly Thr Thr Gly Gly Gly Cys Cys Cys Thr Cys Ala Ala Thr
 50 55 60
 Ala Cys Cys Thr Cys Cys Gly Cys Cys Gly Cys Cys
 65 70 75

<210> 375
 <211> 126
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<220>
 <221> CDS
 <222> (1)..(126)
 <223>

<400> 375
 aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 1 5 10 15
 gct gct cgt gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca 96
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
 20 25 30

acc ctt cgc caa tgg ctt gca gca cgc gca
 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 35 40

<210> 376
 <211> 42
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 376

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
 20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 35 40

<210> 377
 <211> 39
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 377

Thr Thr Thr Thr Thr Thr Cys Ala Thr Ala Thr Gly Ala Thr Cys Gly
 1 5 10 15

Ala Ala Gly Gly Thr Cys Cys Gly Ala Cys Thr Cys Thr Gly Cys Gly
 20 25 30

Thr Cys Ala Gly Thr Gly Gly
 35

<210> 378
 <211> 48
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 378

Ala Gly Cys Ala Cys Gly Ala Gly Cys Ala Gly Cys Cys Ala Gly Cys
 1 5 10 15

Cys Ala Cys Thr Gly Ala Cys Gly Cys Ala Gly Ala Gly Thr Cys Gly
 20 25 30

Gly Ala Cys Cys Thr Thr Cys Gly Ala Thr Cys Ala Thr Ala Thr Gly
 35 40 45

<210> 379
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 379
 ctggctgctc gtgctggtgg aggcgggtggg gacaaaactc acaca 45

<210> 380
 <211> 51
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 380
 ctggctgctc gtgctggcgg tgggtggcgga ggggggtggca ttgagggccc a 51

<210> 381
 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 381
 aagccattgg cgaagggttg ggcctcaat gccacccct cgcaccac cgcc 54

<210> 382
 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 382
 acccttcgcc aatggcttgc agcacgcgca gggggaggcg gtggggacaa aact 54

<210> 383
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 383
 cccaccgcct cccctgcgc gtgctgc 27

<210> 384
 <211> 189
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<220>
 <221> CDS -
 <222> (10)..(180)
 <223>

<400> 384
 ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51
 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 1 5 10
 gct ggc ggt ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99
 Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 15 20 25 30
 caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147
 Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Asp Lys Thr Leu
 35 40 45
 gct gct cgt gct ggt gga ggc ggt ggg gac aaa actcacaca 189
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys
 50 55

<210> 385
 <211> 57
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TMP-TMP-Fc

<400> 385
 Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 1 5 10 15
 Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30
 Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala
 35 40 45
 Arg Ala Gly Gly Gly Gly Gly Asp Lys
 50 55

<210> 386
 <211> 141
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> pAMG21

<400> 386
 ctaattccgc tctcacctac caaacaatgc cccctgcaa aaaataaatt catataaaaa 60
 acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120
 tggcgggtgat actgagcaca t 141

<210> 387
 <211> 55
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> pAMG21

<400> 387
 cgattttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac 55

<210> 388
 <211> 872
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> GM221

<400> 388
 ttatttttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt 60
 gttagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg 120
 gataatatat gagcacaaaa aagaaacat taacacaaga gcagcttgag gacgcacgtc 180
 gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg 240
 cagacaagat ggggatggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat 300
 taaatgctta taacgccgca ttgcttacia aaattctcaa agttagcgtt gaagaattta 360
 gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact 420
 tagaagtgag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa 480
 gcttagaacc ttaccaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag 540
 tgattctgca ttctggcctg aggttgaagg taattccatg aagtcaccaa caggctccaa 600
 gccaaagcttt cctgacggaa tgtaattct cgttgaccct gagcaggctg ttgagccagg 660
 tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga 720
 tagcggtcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga 780
 gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggtcg 840
 atagactagt ggatccacta gtgtttctgc cc 872

<210> 389
 <211> 1197
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> GM221

<400> 389
 ggcggaaacc gacgtccatc gaatggtgca aaaccttttcg cggtatggca tgatagcgcc 60
 cggaagagag tcaattcagg gtggtgaatg tgaaaccagt aacgttatac gatgtcgcag 120
 agtatgccgg tgtctcttat cagaccgttt cccgcgtggg gaaccaggcc agccacgttt 180

A-527.ST25.txt

ctgcgaaaac gcgggaaaaa gtcgaagcgg cgatggcgga gctgaattac attcccaacc	240
gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc	300
tggccctgca cgcgccgctg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg	360
gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg	420
tgcacaatct tctcgcgcaa cgcgctcagt ggctgatcat taactatccg ctggatgacc	480
aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttattt cttgatgtct	540
ctgaccagac acccatcaac agtattattt tctcccatga agacggtagc cgactgggcg	600
tggagcatct ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt	660
ctgtctcggc gcgtctgctg ctggctgggt ggcataaata tctcactcgc aatcaaattc	720
agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaaccatgc	780
aaatgctgaa tgagggcatc gttccctactg cgatgctggt tgccaacgat cagatggcgc	840
tgggcgcaat gcgcgccatt accgagtcgg ggctgcgcgt tggcgggat atctcggtag	900
tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac	960
aggattttcg cctgctgggg caaaccagcg tggaccgctt gctgcaactc tctcagggcc	1020
aggcggtgaa gggcaatcag ctgttgcccg tctcactggt gaaaagaaaa accaccctgg	1080
cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac	1140
gacaggtttc ccgactggaa agcggacagt aaggtaccat aggatccagg cacagga	1197

<210> 390
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 390	
tatgaaaggt ggaggtggtg gtggaggtac ttactcttgc cacttcgggc cgctgacttg	60
g	61

<210> 391
 <211> 72
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 391	
cggtttgcaa acccaagtca gcgggcccga gtggcaagag taagtacctc caccaccacc	60
tccacctttc at	72

<210> 392
 <211> 57
 <212> DNA
 <213> Artificial Sequence


```

<220>
<223> Fc-EMP

<400> 392
gtttgcaaac cgcaggggtg cggcggcggc ggcgggtgga cctattcctg tcatttt      57

<210> 393
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-EMP

<400> 393
ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg      60

<210> 394
<211> 118
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc-EMP

<220>
<221> CDS
<222> (2)..(118)
<223>

<400> 394
t atg aaa ggt gga ggt ggt ggt gga ggt act tac tct tgc cac ttc ggc      49
Met Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly
1 5 10 15

ccg ctg act tgg gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt      97
Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly
20 25 30

ggt acc tat tcc tgt cat ttt      118
Gly Thr Tyr Ser Cys His Phe
35

<210> 395
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc-EMP

<400> 395
Met Lys Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly
1 5 10 15

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly
20 25 30

Gly Thr Tyr Ser Cys His Phe
35

```

<210> 396
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 396
 gcagaagagc ctctccctgt ctccgggtaa aggtggaggt ggtggtggag gtacttactc 60
 t 61

<210> 397
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 397
 ctaattggat ccâcgagatt aaccaccctg cggtttgcaa 40

<210> 398
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 398
 Gly Glu Arg Trp Cys Phe Asp Gly Pro Leu Thr Trp Val Cys Gly Glu
 1 5 10 15

Glu Ser

<210> 399
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP

<400> 399
 agagtaagta cctccaccac cacctccacc tttacccgga gacagggaga ggctcttctg 60
 c 61

<210> 400
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EMP-Fc

A-527.ST25.txt

<400> 400
ggccccgtga cctgggtatg taagccacaa ggggggtgggg gaggcggggg gtaatctcga 60
g 61

<210> 401
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-Fc

<400> 401
gatcctcgag attaccccc gcctcccca ccccttgtg gcttacatac 50

<210> 402
<211> 118
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-Fc

<220>
<221> CDS
<222> (1)..(108)
<223>

<400> 402
gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc 48
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
1 5 10 15

tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg 96
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
20 25 30

gga ggc ggg ggg taatctcgag 118
Gly Gly Gly Gly
35

<210> 403
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> EMP-Fc

<400> 403
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
1 5 10 15

Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
20 25 30

Gly Gly Gly Gly
35

<210> 404
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-Fc

 <400> 404
 ttatttcata tgaaagggtgg taactattcc tgtcatttt 39

<210> 405
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-Fc

 <400> 405
 tggacatgtg tgagttttgt ccccccgcc tccccaccc cct 43

<210> 406
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-Fc

 <400> 406
 aggggggtggg ggaggcgggg gggacaaaac tcacacatgt cca 43

<210> 407
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-Fc

 <400> 407
 gttattgctc agcgggtggca 20

<210> 408
 <211> 60
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-EMP-Fc

 <400> 408
 ttttttatcg atttgattct agatttgagt ttttaactttt agaaggagga ataaaatatg 60

<210> 409
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> EMP-EMP-Fc

<400> 409
taaaagttaa aactcaaata tagaatcaaa tcgataaaaa a 41

<210> 410
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 410
ggaggtactt actcttgcca cttcggcccg ctgacttggg ttgcaaacc g 51

<210> 411
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 411
agtcagcggg ccgaagtggc aagagtaagt acctccata tttattcct ccttc 55

<210> 412
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 412
cagggtggcg gcggcggcgg cggtggtacc tattcctgtc attttggccc gctgacctgg 60

<210> 413
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 413
aaaatgacag gaataggtac caccgccgcc gccgccgcca ccctgcgggt tgcaaaccga 60

<210> 414
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 414
gtatgtaagc cacaaggggg tgggggaggc gggggggaca aaactcacac atgtcca 57

<210> 415
<211> 60
<212> DNA
<213> Artificial Sequence

```

<220>
<223> EMP-EMP-Fc

<400> 415
agttttgtcc cccccgcctc cccaccccc ttgtggctta catacccagg tcagcgggcc      60

<210> 416
<211> 228
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<220>
<221> CDS
<222> (58)..(228)
<223>

<400> 416
ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat      57
atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc      105
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat      153
Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20 25 30

ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc      201
Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35 40 45

ggg ggg gac aaa act cac aca tgt cca      228
Gly Gly Asp Lys Thr His Thr Cys Pro
50 55

<210> 417
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> EMP-EMP-Fc

<400> 417
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20 25 30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35 40 45

Gly Gly Asp Lys Thr His Thr Cys Pro
50 55

```

<210> 418
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-EMP-EMP

<400> 418
 ctaattggat cctcgagatt aacccccttg tggcttacat

40

<210> 419
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 3, 9, 14, 15)..(16)
 <223> Xaa (Positions 1, 3, 9, 14, 15 & 16) can be any one of the 20 L-amino acids

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa can be R, H, L or W

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be M, F or I

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Xaa can be D, E, I, L or V

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> Xaa can be C, A, a-amino-y-bromobutyric acid or Hoc

<400> 419

Xaa Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

<210> 420
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 3, 5, 6, 9, 12, 14, 15)..(16)

<223> Xaa = any amino acid residue

<400> 420

Xaa Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 421

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be R, H, L, or W

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be M, F, or I

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa is independently selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa can be D, E, I, L, or V.

<400> 421

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys
1 5 10

<210> 422

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 422

Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro
1 5 10 15

Gln Gly Gly

<210> 423

<211> 19

<212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 423

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly

<210> 424
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 424

Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp
 1 5 10 15

Ile Cys

<210> 425
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 425

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln

<210> 426
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 426

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
 1 5 10 15

Pro Leu Arg Gly
 20

<210> 427
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 427

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
 1 5 10 15

Arg Pro Ser Pro Lys Ala
 20

<210> 428
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 428

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 429
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 429

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10

<210> 430
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE

<400> 430

Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr
 1 5 10 15

Tyr

<210> 431
 <211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 431

Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg
1 5 10 15

Thr

<210> 432
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 432

Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser
1 5 10 15

Ala

<210> 433
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (4, 5)..(6)
<223> Xaa = any amino acid

<400> 433

Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu
1 5 10

<210> 434
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> UKR ANTAGONIST PEPTIDE

<400> 434

Ala Glu Ser Thr Tyr His His Leu Ser Leu Gly Tyr Met Tyr Thr Leu
1 5 10 15

Asn

<210> 435
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> UKR ANTAGONIST PEPTIDE

 <220>
 <221> misc_feature
 <222> (3, 5)..(6)
 <223> Xaa = any amino acid

<400> 435

Tyr His Xaa Leu Xaa Xaa Gly Tyr Met Tyr Thr
 1 5 10

<210> 436
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

 <400> 436

Arg Asn Arg Gln Lys Thr
 1 5

<210> 437
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

 <400> 437

Arg Asn Arg Gln
 1

<210> 438
 <211> 5
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

 <400> 438

Arg Asn Arg Gln Lys
 1 5

<210> 439
 <211> 5

<212> PRT
 <213> Artificial Sequence
 <220>
 <223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE
 <400> 439

Asn Arg Gln Lys Thr
 1 5

<210> 440
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE
 <400> 440

Arg Gln Lys Thr
 1

<210> 441
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <220>
 <221> misc_feature
 <222> (2, 5)..(7)
 <223> Xaa = any amino acid

<400> 441

Arg Xaa Glu Thr Xaa Trp Xaa
 1 5

<210> 442
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <220>
 <221> misc_feature
 <222> (2, 5)..(7)
 <223> Xaa = any amino acid

<400> 442

Arg Xaa Glu Thr Xaa Trp Xaa
 1 5

<210> 443
 <211> 5

<212> PRT
 <213> Artificial Sequence

 <220>
 <223> INTEGRIN-BINDING PEPTIDE

 <220>
 <221> misc_feature
 <222> (5)..(6)
 <223> Xaa = any amino acid

<400> 443

Arg Gly Asp Gly Xaa
 1 5

<210> 444
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> INTEGRIN-BINDING PEPTIDE

 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa = any amino acid

<400> 444

Cys Arg Gly Asp Gly Xaa Cys
 1 5

<210> 445
 <211> 15
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> INTEGRIN-BINDING PEPTIDE

 <220>
 <221> misc_feature
 <222> (2, 3, 4, 8, 9, 10, 11, 12, 13)..(14)
 <223> Xaa = any amino acid

<400> 445

Cys Xaa Xaa Xaa Arg Leu Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
 1 5 10 15

<210> 446
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> INTEGRIN-BINDING PEPTIDE

 <400> 446

Cys Ala Arg Arg Leu Asp Ala Pro Cys
1 5

<210> 447
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 447

Cys Pro Ser Arg Leu Asp Ser Pro Cys
1 5

<210> 448
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<220>
<221> misc_feature
<222> (1, 2, 3, 7, 8)..(9)
<223> Xaa are capable of forming a cyclizing bond

<220>
<221> misc_feature
<222> (2)..(5)
<223> Feature at 1, 5 is an amino acid capable of forming a cyclizing bond and attached to 1-5 amino acid linker

<400> 448

Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa
1 5

<210> 449
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa = any amino acid

<400> 449

Cys Xaa Cys Arg Gly Asp Cys Xaa Cys
1 5

<210> 450
<211> 9
<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 450 -

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 451

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 451

Cys Asp Cys Arg Gly Asp Cys Leu Cys
1 5

<210> 452

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 452

Cys Leu Cys Arg Gly Asp Cys Ile Cys
1 5

<210> 453

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 5, 6, 7)..(8)

<223> Xaa = any amino acid

<400> 453

Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa
1 5

<210> 454

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature
 <222> (1, 2, 3, 6, 7, 8, 9)..(10)
 <223> Xaa = any amino acid

<400> 454 -

Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa
 1 5 10

<210> 455
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 455

Cys Trp Asp Asp Gly Trp Leu Cys
 1 5

<210> 456
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 456

Cys Trp Asp Asp Leu Trp Trp Leu Cys
 1 5

<210> 457
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 457

Cys Trp Asp Asp Gly Leu Met Cys
 1 5

<210> 458
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 458

Cys Trp Asp Asp Gly Trp Met Cys
 1 5

<210> 459

<211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 459

Cys Ser Trp Asp Asp Gly Trp Leu Cys
 1 5

<210> 460
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 460

Cys Pro Asp Asp Leu Trp Trp Leu Cys
 1 5

<210> 461
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (2)..(8)
 <223> Xaa can be any of the 20 L-amino acids

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Xaa can be C, A, α -amino- γ -bromobutyric acid or Hoc

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Xaa can be R, H, L or W

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa can be M, F or I; Xaa

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Xaa can be D, E, I, L or V

<220>
 <221> misc_feature
 <222> (12)..(12)

<223> Xaa can be C, A, a-amino-γ-bromobutyric acid or Hoc; provided that Xaa (Pos3 or 12) is C or Hoc.

<400> 461

Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
1 5 10

<210> 462

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 462

Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu
1 5 10 15

<210> 463

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 463

Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu
1 5 10 15

Asp

<210> 464

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 464

Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu
1 5 10 15

Thr Asn Glu

<210> 465

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 465

Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp
 1 5 10

<210> 466
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (3)..(15)
 <223> Xaa = any amino acid

<400> 466

Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu
 1 5 10 15

<210> 467
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (3, 5, 6, 13)..(15)
 <223> Xaa = any amino acid

<400> 467

Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu
 1 5 10 15

Thr Glu Glu

<210> 468
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (13)..(15)
 <223> Xaa = any amino acid

<400> 468

Ala Glu Asn Trp Ala Asp Gly Glu Pro Asn Asn Lys Xaa Asn Xaa Glu
 1 5 10 15

Asp

<210> 469
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 3, 4, 7)..(15)
 <223> Xaa = any amino acid

<400> 469

Cys	Xaa	Xaa	Xaa	Tyr	Thr	Xaa	Leu	Val	Ala	Ile	Gln	Asn	Lys	Xaa	Glu
1				5					10					15	

<210> 470
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (3, 4, 5, 6, 8, 13, 15)..(18)
 <223> Xaa = any amino acid

<400> 470

Arg	Lys	Xaa	Xaa	Xaa	Xaa	Trp	Xaa	Trp	Val	Gly	Thr	Xaa	Lys	Xaa	Leu
1				5					10					15	

Thr Xaa Glu

<210> 471
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 5, 6, 7, 12, 13)..(14)
 <223> Xaa = any amino acid

<400> 471

Ala	Xaa	Asn	Trp	Xaa	Xaa	Xaa	Glu	Pro	Asn	Asn	Xaa	Xaa	Xaa	Glu	Asp
1				5					10					15	

<210> 472
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1, 3, 6, 9, 12)..(13)
 <223> Xaa = any amino acid

<400> 472

Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa
 1 5 10

<210> 473
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Xaa is Asp-Arg-Met-Pro-Cys, Arg-Met-Pro-Cys, Met-Pro-Cys, Pro-Cys
 or Cys

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Xaa is Arg or Lys

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Xaa is Ser or Thr

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Xaa is Cys-Lys or Cys

<400> 473

Xaa Xaa Asn Phe Phe Trp Lys Thr Phe Xaa Ser Xaa
 1 5 10

<210> 474
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 474

Asp	Arg	Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys
1				5					10					15	

Lys

<210> 475

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 475

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1				5				10					15	

<210> 476

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 476

Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys	Lys
1			5				10					

<210> 477

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 477

Asp	Arg	Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys
1				5					10					15	

<210> 478

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 478

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Ser	Ser	Cys
1				5				10					

<210> 479

<211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 479

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10

<210> 480
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 480

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10 15

<210> 481
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 481

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
 1 5 10 15

<210> 482
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 482

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
 1 5 10

<210> 483
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 483

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10 15

<210> 484
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 484

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10

<210> 485
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 485

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10

<210> 486
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 486

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
 1 5 10 15

Lys

<210> 487
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 487

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
 1 5 10 15

<210> 488
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 Page 149

<400> 488

Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10

<210> 489

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 489

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

<210> 490

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 490

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 491

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 491

Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 492

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 492

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

Lys

<210> 493

<211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 493

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
 1 5 10 15

<210> 494
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 494

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
 1 5 10

<210> 495
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 495

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
 1 5 10 15

<210> 496
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 496

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
 1 5 10

<210> 497
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 497

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
 1 5 10

<210> 498
 <211> 25
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CAP37 MIMETIC/LPS BINDING

<400> 498

Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe
 1 5 10 15

Val Met Thr Ala Ala Ser Cys Phe Gln
 20 25

<210> 499
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CAP37 MIMETIC/LPS BINDING

<400> 499

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
 1 5 10 15

Ala Ala Ser Cys
 20

<210> 500
 <211> 27
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CAP37 MIMETIC/LPS BINDING

<400> 500

Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly
 1 5 10 15

Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val
 20 25

<210> 501
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF- ANTAGONIST

<400> 501

Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp
 1 5 10 15

Glu Ile

<210> 502 -
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF- ANTAGONIST

<400> 502

Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr
 1 5 10 15

Val Lys

<210> 503
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 503

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
 1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
 20 25 30

Gln

<210> 504
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<220>
 <221> misc_feature
 <222> (7, 18,...)(19)
 <223> Positions 7, 18, and 19, D amino acid residue

<400> 504

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
 1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
 20 25 30

Glu

<210> 505 -
 <211> 22
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> ANTIPATHOGENIC PEPTIDE

 <220>
 <221> misc_feature
 <222> (18)..(19)
 <223> Positions 18 and 19, D amino acid residues

<400> 505

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	

Thr	Leu	Leu	Ser	Ala	Val
					20

<210> 506
 <211> 22
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> ANTIPATHOGENIC PEPTIDE

 <220>
 <221> misc_feature
 <222> (7, 18)..(19)
 <223> Positions 7, 18 and 19, D amino acid residues

<400> 506

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	

Thr	Leu	Leu	Ser	Ala	Val
					20

<210> 507
 <211> 23
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> ANTIPATHOGENIC PEPTIDE

 <220>
 <221> misc_feature
 <222> (8, 19)..(20)
 <223> Positions 8, 19 and 20, D amino acid residues

<400> 507

Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe
1 5 10 15

Lys Thr Leu Leu Ser Ala Val
20

<210> 508
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (9, 20)..(21)
<223> Positions 9, 20 and 21, D amino acid residues

<400> 508

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
1 5 10 15

Phe Lys Thr Leu Leu Ser Ala Val
20

<210> 509
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (9, 20)..(21)
<223> Positions 9, 20 and 21, D amino acid residues

<400> 509

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
1 5 10 15

Phe Lys Thr Leu Leu Ser Ala Val
20

<210> 510
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (7)..(7)

<223> Position 7, D amino acid residue

<400> 510

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser
1 5 10

<210> 511

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 511

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 512

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 8, 17)..(23)

<223> Positions 5, 8, 17 and 23, D amino acid residues

<400> 512

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 513

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 18, 17)..(23)

<223> Positions 5, 18, 17 and 23, D amino acid residues

<400> 513

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
Page 156

1 5 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 514
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (5, 8, 17)..(21)
<223> Positions 5, 8, 17 and 21, D amino acid residues

<400> 514

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg
20

<210> 515
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (2, 5, 14)..(18)
<223> Positions 2, 5, 14 and 18, D amino acid residues

<400> 515

Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu Ile Ser Trp
1 5 10 15

Ile Lys Arg

<210> 516
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<220>
<221> misc_feature
<222> (3, 4, 8)..(10)
<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 516

Lys Leu Leu Leu Leu Leu Lys Leu Leu Leu Leu Lys
 1 5 10

<210> 517

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 517

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 518

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 518

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 519

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 519

Lys Lys Leu Leu Lys Leu Lys Leu Lys Leu Lys Lys
 1 5 10

<210> 520

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 520

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 521

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 521

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 522

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 522

Lys Leu Leu Leu Leu Lys
 1 5

<210> 523

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 523

Lys Leu Leu Leu Lys Leu Leu Lys
 1 5

<210> 524

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 524

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 525

<211> 12

<212> PRT

<213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 525

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Lys
 1 5 10

<210> 526
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 526

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Lys
 1 5 10

<210> 527
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 527

Lys Ala Ala Ala Lys Ala Ala Ala Lys Ala Ala Lys
 1 5 10

<210> 528
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 528

Lys Val Val Val Lys Val Val Val Lys Val Val Lys
 1 5 10

<210> 529
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 529

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
 1 5 10

<210> 530
 <211> 11
 <212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 530 -

Lys Val Val Val Lys Val Lys Val Lys Val Lys
1 5 10

<210> 531

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 531

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
1 5 10

<210> 532

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 532

Lys Leu Ile Leu Lys Leu
1 5

<210> 533

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 533

Lys Val Leu His Leu Leu
1 5

<210> 534

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 534

Leu Lys Leu Arg Leu Leu
1 5

<210> 535

<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 535

Lys Pro Leu His Leu Leu
1 5

<210> 536
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 536

Lys Leu Ile Leu Lys Leu Val Arg
1 5

<210> 537
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 537

Lys Val Phe His Leu Leu His Leu
1 5

<210> 538
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 538

His Lys Phe Arg Ile Leu Lys Leu
1 5

<210> 539
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 539

Lys Pro Phe His Ile Leu His Leu
1 5

<210> 540
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 540

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 541
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 541

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 542
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 542

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 543
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 543

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Pro Lys
1 5 10

<210> 544
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 544

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Val Lys
Page 163

1 5 10

<210> 545
<211> 12
<212> PRT -
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 545

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 546
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 546

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 547
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 547

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 548
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 548

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 549
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 549

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg
 1 5 10

<210> 550 -
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 550

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg
 1 5 10

<210> 551
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 551

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
 1 5 10

<210> 552
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 552

Arg Ile Ala Val Lys Trp Arg Leu Arg Phe Ile Lys
 1 5 10

<210> 553
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 553

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg
 1 5 10

<210> 554
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 554

Lys Lys Ile Gly Trp Leu Ile Ile Arg Val Arg Arg
 1 5 10

<210> 555

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 555

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
 1 5 10

<210> 556

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 556

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg Val Arg
 1 5 10

<210> 557

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 557

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg Arg Val
 1 5 10

<210> 558

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 558

Lys Ile Val Ile Arg Ile Arg Ala Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15

<210> 559

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 559

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 560

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 560

Lys Ile Gly Ile Lys Ala Arg Val Arg Ile Ile Arg Val Lys Ile Ile
 1 5 10 15

<210> 561

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 561

Arg Ile Ile Val His Ile Arg Leu Arg Ile Ile His His Ile Arg Leu
 1 5 10 15

<210> 562

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 562

His Ile Gly Ile Lys Ala His Val Arg Ile Ile Arg Val His Ile Ile
 1 5 10 15

<210> 563

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 563

Arg Ile Tyr Val Lys Ile His Leu Arg Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 564

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 564

Lys Ile Gly His Lys Ala Arg Val His Ile Ile Arg Tyr Lys Ile Ile
 1 5 10 15

<210> 565

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 565

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 566

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 566

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
 1 5 10 15

<210> 567

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 567

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15

Lys Ile Val

<210> 568

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 568

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

Ile Lys Lys

<210> 569
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 569

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
 1 5 10 15

Arg Leu Arg

<210> 570
 <211> 25
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 570

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
 1 5 10 15

Lys Ile Val Lys Val Lys Arg Ile Arg
 20 25

<210> 571
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 571

Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
 1 5 10 15

Ile Lys Lys Ile Arg Lys Arg Val Ile Lys
 20 25

<210> 572
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 572

A-527.ST25.txt

Lys Ala Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
1 5 10 15

Arg Leu Arg Lys Ile Gly Trp Lys Lys Arg Val Arg Ile Lys
20- 25 30

<210> 573
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 573

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 574
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 574

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 575
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 575

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

Lys Ile Val

<210> 576
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE

<400> 576

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys

<210> 577
 <211> 16 -
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 577

Arg Ile Tyr Val Ser Lys Ile Ser Ile Tyr Ile Lys Lys Ile Arg Leu
 1 5 10 15

<210> 578
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 578

Lys Ile Val Ile Phe Thr Arg Ile Arg Leu Thr Ser Ile Arg Ile Arg
 1 5 10 15

Ser Ile Val

<210> 579
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 579

Lys Pro Ile His Lys Ala Arg Pro Thr Ile Ile Arg Tyr Lys Met Ile
 1 5 10 15

<210> 580
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, disulfide bond to position 26

<220>
 <221> misc_feature
 <222> (26)..(26)
 <223> Position 26, disulfide bond to position 1
 Page 171

<400> 580

Xaa Cys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro
1 5 10 15

Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
 20 25

<210> 581

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 581

Cys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro
1 5 10 15

Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
 20 25

<210> 582

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 582

Cys Lys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser
1 5 10 15

Pro Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
 20 25

<210> 583

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 17

<220>

<221> misc_feature

<222> (17)..(17)

<223> Position 17, disulfide bond to position 1

<400> 583

Xaa Cys Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
 1 5 10 15

Cys

<210> 584

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 19

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, disulfide bond to position 1

<400> 584

Xaa Cys Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys
 1 5 10 15

Ile Ile Cys

<210> 585

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 29

<220>

<221> misc_feature

<222> (29)..(29)

<223> Position 29, disulfide bond to position 1

<400> 585

Xaa Cys Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile
 1 5 10 15

Arg Leu Ile Lys Lys Ile Arg Lys Arg Val Ile Lys Cys
 20 25

<210> 586
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 586

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys Cys
 1 5 10

<210> 587
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 587

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 588
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 588

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys Cys
 1 5 10

<210> 589
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE

<400> 589

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 590
 <211> 28
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 590

A-527.ST25.txt

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
20- 25

<210> 591
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 591

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
20 25

<210> 592
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is L-Lys, D-Lys or an ornithinyl residue

<220>
<221> misc_feature
<222> (2)..(2)
<223> Position 2, Xaa is L-Tyr, D-Tyr, Phe, Trp or a p-aminophenylalany
1 residue

<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3 is a hydrophobic aliphatic amino acid residue, Positio
n 3, optional attachment to Leu, norleucyl, D-Ala, Asn-Ser, Asn-S
er-Ile-, Asn-Ser-Tyr, Ser-Ile-Leu, Asn-Ser-Tyr-Leu or Asn-Ser-Tyr
-Leu-Asn

<400> 592

Xaa Xaa Xaa
1

<210> 593
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 1, Xaa is either absent, a hydrophobic aliphatic residue (X5), X5-Asn, Tyr-X5, Lys-X5, Lys-X5-Asn, Lys-Tyr-X5, Lys-Tyr-X5-Asn, Lys-Lys-Tyr-X5, Lys-Lys-Tyr-X5-Asn, Val-Lys-Lys-Tyr-X5, Val-Ala-Lys-Lys-Tyr-X5-Asn, or Ala-Val-Lys-Lys-Tyr-X5-Asn

<400> 593

Xaa Ser Xaa Leu Asn

1

5

<210> 594

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1, 5, 6)..(7)

<223> Positions 1 and 6, Xaa are cross-linked amino acid residues as defined in W097/40070

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a hydrophobic aliphatic aminod acid residue

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, is a covalent bond or Asn, Ser, Ile, Tyr, Leu, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Tyr, Asn-Ser-Ile-Leu, Asn-Ser-Tyr-Leu, Asn-Ser-Ile-Leu-Asn or Asn-Ser-Tyr-Leu-Asn.

<400> 594

Xaa Lys Lys Tyr Xaa Xaa Xaa

1

5

<210> 595

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 595

Lys Lys Tyr Leu

1

<210> 596

<211> 5

<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 596

Asn Ser Ile Leu Asn
1 5

<210> 597
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 597

Lys Lys Tyr Leu
1

<210> 598
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 598

Lys Lys Tyr Ala
1

<210> 599
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 599

Ala Val Lys Lys Tyr Leu
1 5

<210> 600
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 600

Ser Ile Leu Asn
1

<210> 601
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 601

Lys Lys Tyr Val
1

<210> 602
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3, Xaa is a lauric acid residue

<400> 602

Ser Ile Xaa Asn
1

<210> 603
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is a norleucyl residue

<400> 603

Lys Lys Tyr Leu Xaa
1 5

<210> 604
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 604

Asn Ser Tyr Leu Asn
1 5

<210> 605
<211> 5
<212> PRT
<213> Artificial Sequence

<220> -
<223> VIP-MIMETIC PEPTIDE

<400> 605

Asn Ser Ile Tyr Asn
1 5

<210> 606
<211> 11
<212> PRT
<213> Artificial Sequence

<220> .
<223> VIP-MIMETIC PEPTIDE

<400> 606

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 607
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is a lauric acid residue

<400> 607

Xaa Lys Lys Tyr Leu
1 5

<210> 608
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is a caproic acid residue

<400> 608

Xaa Lys Lys Tyr Leu
1 5

<210> 609
<211> 4
<212> PRT
<213> Artificial Sequence

<220> -
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is a norleucyl residue

<400> 609

Lys Lys Tyr Xaa
1

<210> 610
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 610

Val Lys Lys Tyr Leu
1 5

<210> 611
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 611

Leu Asn Ser Ile Leu Asn
1 5

<210> 612
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 612

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 613
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<210> 632
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(3)
 <223> Position 3, Xaa is a lauric acid residue

<400> 632

Xaa Ile Xaa Asn
 1

<210> 633
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a lauric acid residue

<400> 633

Xaa Lys Lys Tyr Leu
 1 5

<210> 634
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a caproic acid residue

<400> 634

Xaa Lys Lys Tyr Leu
 1 5

<210> 635
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is a norleucyl residue

<400> 635

Lys Lys Tyr Xaa
1

<210> 636
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 636

Val Lys Lys Tyr Leu
1 5

<210> 637
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 637

Leu Asn Ser Ile Leu Asn
1 5

<210> 638
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 638

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 639
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is a norleucyl residue

<400> 639

Lys Lys Tyr Leu Xaa
1 5

<210> 640

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 640

Lys Lys Tyr Leu Asn
1 5

<210> 641

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 641

Lys Lys Tyr Leu Asn Ser
1 5

<210> 642

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 642

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 643

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 643

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 644

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 644

Lys Lys Lys Tyr Leu Asp
1 - 5

<210> 645

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Positions 1 and 6 disulfide cross-linked

<400> 645

Xaa Cys Lys Lys Tyr Leu Cys
1 5

<210> 646

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Positions 1 and 6 cross-linked by S-CH₂-CO

<400> 646

Cys Lys Lys Tyr Leu Lys
1 5

<210> 647

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Position 4, D amino acid residue

<400> 647

Lys Lys Tyr Ala
1

<210> 648

<211> 8

<212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 648 -

Trp Trp Thr Asp Thr Gly Leu Trp
 1 5

<210> 649
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 649

Trp Trp Thr Asp Asp Gly Leu Trp
 1 5

<210> 650
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 650

Trp Trp Asp Thr Arg Gly Leu Trp Val Trp Thr Ile
 1 5 10

<210> 651
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 651

Phe Trp Gly Asn Asp Gly Ile Trp Leu Glu Ser Gly
 1 5 10

<210> 652
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 652

Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
 1 5 10

<210> 653
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 653

Arg Trp Asp Asp Asn Gly Leu Trp Val Val Val Leu
1 5 10

<210> 654

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 654

Ser Gly Met Trp Ser His Tyr Gly Ile Trp Met Gly
1 5 10

<210> 655

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 655

Gly Gly Arg Trp Asp Gln Ala Gly Leu Trp Val Ala
1 5 10

<210> 656

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 656

Lys Leu Trp Ser Glu Gln Gly Ile Trp Met Gly Glu
1 5 10

<210> 657

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 657

Cys Trp Ser Met His Gly Leu Trp Leu Cys
1 5 10

<210> 658

<211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 658

Gly Cys Trp Asp Asn Thr Gly Ile Trp Val Pro Cys
 1 5 10

<210> 659
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 659

Asp Trp Asp Thr Arg Gly Leu Trp Val Tyr
 1 5 10

<210> 660
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 660

Ser Leu Trp Asp Glu Asn Gly Ala Trp Ile
 1 5 10

<210> 661
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 661

Lys Trp Asp Asp Arg Gly Leu Trp Met His
 1 5 10

<210> 662
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<400> 662

Gln Ala Trp Asn Glu Arg Gly Leu Trp Thr
 1 5 10

<210> 663
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 663

Gln Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 664
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 664

Trp Asn Val His Gly Ile Trp Gln Glu
1 5

<210> 665
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 665

Ser Trp Asp Thr Arg Gly Leu Trp Val Glu
1 5 10

<210> 666
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 666

Asp Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 667
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 667

Ser Trp Gly Arg Asp Gly Leu Trp Ile Glu
Page 192


```

1                5                10

<210> 668
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 668

Glu Trp Thr Asp Asn Gly Leu Trp Ala Leu
1                5                10

<210> 669
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 669

Ser Trp Asp Glu Lys Gly Leu Trp Ser Ala
1                5                10

<210> 670
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 670

Ser Trp Asp Ser Ser Gly Leu Trp Met Asp
1                5                10

<210> 671
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 671

Ser His Leu Tyr Trp Gln Pro Tyr Ser Val Gln
1                5                10

<210> 672
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 672

```

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Leu Gln Thr
 1 5 10

<210> 673
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 673

Arg Gly Asp Tyr Trp Gln Pro Tyr Ser Val Gln Ser
 1 5 10

<210> 674
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 674

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10

<210> 675
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 675

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10

<210> 676
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 676

Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
 1 5 10

<210> 677
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 677

Asn Met Val Tyr Trp Gln Pro Tyr Ser Ile Gln Thr
 1 5 10

<210> 678

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 678

Ser Val Val Phe Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10

<210> 679

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 679

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 680

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 680

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
 1 5 10

<210> 681

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 681

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 682

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 682

Ser	Pro	Val	Phe	Trp	Gln	Pro	Tyr	Ser	Ile	Gln	Ile
1				5					10		

<210> 683

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 683

Trp	Ile	Glu	Trp	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Ser
1				5					10		

<210> 684

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 684

Ser	Leu	Ile	Tyr	Trp	Gln	Pro	Tyr	Ser	Leu	Gln	Met
1				5					10		

<210> 685

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 685

Thr	Arg	Leu	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Arg
1				5					10		

<210> 686

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 686

Arg	Cys	Asp	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Thr
1				5					10		

<210> 687

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 687

Met Arg Val Phe Trp Gln Pro Tyr Ser Val Gln Asn
1 - 5 10

<210> 688

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 688

Lys Ile Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 689

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 689

Arg His Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 690

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 690

Ala Leu Val Trp Trp Gln Pro Tyr Ser Glu Gln Ile
1 5 10

<210> 691

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 691

Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 692

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 692

Trp Glu Gln Pro Tyr Ala Leu Pro Leu Glu
 1 5 10

<210> 693

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 693

Gln Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 694

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 694

Asp Leu Arg Tyr Trp Gln Pro Tyr Ser Val Gln Val
 1 5 10

<210> 695

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 695

Glu Leu Val Trp Trp Gln Pro Tyr Ser Leu Gln Leu
 1 5 10

<210> 696

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 696

Asp Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Trp
 1 5 10

<210> 697

<211> 12

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 697

Asn Gly Asn Tyr Trp Gln Pro Tyr Ser Phe Gln Val
 1 5 10

<210> 698
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 698

Glu Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
 1 5 10

<210> 699
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 699

Glu Leu Met Tyr Trp Gln Pro Tyr Ser Val Gln Glu
 1 5 10

<210> 700
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 700

Asn Leu Leu Tyr Trp Gln Pro Tyr Ser Met Gln Asp
 1 5 10

<210> 701
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 701

Gly Tyr Glu Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 702
<211> 12
<212> PRT
<213> Artificial Sequence

<220> -
<223> IL-1 ANTAGONIST PEPTIDE

<400> 702

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 703
<211> 12
<212> PRT
<213> Artificial Sequence

<220> -
<223> IL-1 ANTAGONIST PEPTIDE

<400> 703

Leu Ser Glu Gln Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 704
<211> 12
<212> PRT
<213> Artificial Sequence

<220> -
<223> IL-1 ANTAGONIST PEPTIDE

<400> 704

Gly Gly Gly Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 705
<211> 12
<212> PRT
<213> Artificial Sequence

<220> -
<223> IL-1 ANTAGONIST PEPTIDE

<400> 705

Val Gly Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 706
<211> 12
<212> PRT
<213> Artificial Sequence

<220> -
<223> IL-1 ANTAGONIST PEPTIDE

<400> 706

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 707
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 707

Gln Ala Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 708
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 708

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
 1 5 10

<210> 709
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 709

Arg Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 710
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 710

Thr Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 711
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 711

Gly Arg Ile Trp Phe Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 712
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 712

Gly Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 713
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 713

Ala Arg Thr Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 714
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 714

Ala Arg Val Trp Trp Gln Pro Tyr Ser Val Gln Met
 1 5 10

<210> 715
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 715

Arg Leu Met Phe Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 716
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 716

Glu Ser Met Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 717

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 717

His Phe Gly Trp Trp Gln Pro Tyr Ser Val His Met
 1 5 10

<210> 718

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 718

Ala Arg Phe Trp Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 719

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 719

Arg Leu Val Tyr Trp Gln Pro Tyr Ala Pro Ile Tyr
 1 5 10

<210> 720

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 720

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Tyr Gln Thr
 1 5 10

<210> 721

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 721

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Leu Pro Ile
1 5 10

<210> 722

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 722

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Ala
1 5 10

<210> 723

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 723

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Lys Gly Leu
1 5 10

<210> 724

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 724

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Gln Gly Leu
1 5 10

<210> 725

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 725

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Met Pro Leu
1 5 10

<210> 726

<211> 12

<212> PRT

<213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 726
 Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Ala
 1 5 10

<210> 727
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 727

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Leu Gly Leu
 1 5 10

<210> 728
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 728

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Arg Glu Leu
 1 5 10

<210> 729
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 729

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Arg Gln Pro
 1 5 10

<210> 730
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 730

Ser Arg Val Trp Tyr Gln Pro Tyr Phe Val Gln Pro
 1 5 10

<210> 731
 <211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 731
Glu Tyr Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 732
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 732

Ile Pro Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 733
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 733

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 734
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 734

Asp Pro Leu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 735
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 735

Ser Arg Gln Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 736
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 736

Ile Arg Ser Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 737
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 737

Arg Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 738
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 738

Arg Leu Leu Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 739
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 739

Glu Tyr Arg Trp Phe Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 740
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 740

Asp Ala Tyr Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 741
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 741

Trp Ser Gly Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 742
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 742

Asn Ile Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 743
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 743

Thr Arg Asp Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 744
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 744

Asp Ser Ser Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 745
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 745

Ile Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 746
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 746

Asn Leu Arg Trp Asp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 747
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 747

Leu Pro Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 748
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 748

Asp Ser Tyr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 749
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 749

Arg Ser Gln Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 750
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 750

Ala Arg Phe Trp Leu Gln Pro Tyr Ala Leu Pro Leu
 Page 209

1

5

10

<210> 751
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 751

Asn Ser Tyr Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 752
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 752

Arg Phe Met Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 753
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 753

Ala His Leu Phe Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 754
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 754

Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5

<210> 755
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 755

Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 756 -
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 756

Tyr Phe Gln Pro Tyr Ala Leu Gly Leu
1 5

<210> 757
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 757

Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 758
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 758

Arg Trp Trp Gln Pro Tyr Ala Thr Pro Leu
1 5 10

<210> 759
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 759

Gly Trp Tyr Gln Pro Tyr Ala Leu Gly Phe
1 5 10

<210> 760
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 760

Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu
 1 5 10

<210> 761

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 761

Ile Trp Tyr Gln Pro Tyr Ala Met Pro Leu
 1 5 10

<210> 762

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 762

Ser Asn Met Gln Pro Tyr Gln Arg Leu Ser
 1 5 10

<210> 763

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 763

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Val Gly Leu Pro Ala Ala Glu
 1 5 10 15

Thr Ala Cys Asn
 1 20

<210> 764

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 764

Thr Phe Val Tyr Trp Gln Pro Tyr Ser Val Gln Met Thr Ile Thr Gly
 1 5 10 15

Lys Val Thr Met
 1 20

<210> 765
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (12, 13)..(16)
 <223> Xaa = any amino acid

<400> 765

Thr Phe Val Tyr Trp Gln Pro Tyr Ser Ser His Xaa Xaa Val Pro Xaa
 1 5 10 15

Gly Phe Pro Leu
 20

<210> 766
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 766

Thr Phe Val Tyr Trp Gln Pro Tyr Tyr Gly Asn Pro Gln Trp Ala Ile
 1 5 10 15

His Val Arg His
 20

<210> 767
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 767

Thr Phe Val Tyr Trp Gln Pro Tyr Val Leu Leu Glu Leu Pro Glu Gly
 1 5 10 15

Ala Val Arg Ala
 20

<210> 768
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 768

Thr Phe Val Tyr Trp Gln Pro Tyr Val Asp Tyr Val Trp Pro Ile Pro
1 5 10 15

Ile Ala Gln Val
20

<210> 769

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 769

Gly Trp Tyr Gln Pro Tyr Val Asp Gly Trp Arg
1 5 10

<210> 770

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 770

Arg Trp Glu Gln Pro Tyr Val Lys Asp Gly Trp Ser
1 5 10

<210> 771

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 771

Glu Trp Tyr Gln Pro Tyr Ala Leu Gly Trp Ala Arg
1 5 10

<210> 772

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 772

Gly Trp Trp Gln Pro Tyr Ala Arg Gly Leu
1 5 10

<210> 773

<211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 773

Leu Phe Glu Gln Pro Tyr Ala Lys Ala Leu Gly Leu
1 5 10

<210> 774
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 774

Gly Trp Glu Gln Pro Tyr Ala Arg Gly Leu Ala Gly
1 5 10

<210> 775
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 775

Ala Trp Val Gln Pro Tyr Ala Thr Pro Leu Asp Glu
1 5 10

<210> 776
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 776

Met Trp Tyr Gln Pro Tyr Ser Ser Gln Pro Ala Glu
1 5 10

<210> 777
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 777

Gly Trp Thr Gln Pro Tyr Ser Gln Gln Gly Glu Val
1 5 10

<210> 778
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 778

Asp Trp Phe Gln Pro Tyr Ser Ile Gln Ser Asp Glu
 1 5 10

<210> 779
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 779

Pro Trp Ile Gln Pro Tyr Ala Arg Gly Phe Gly
 1 5 10

<210> 780
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 780

Arg Pro Leu Tyr Trp Gln Pro Tyr Ser Val Gln Val
 1 5 10

<210> 781
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 781

Thr Leu Ile Tyr Trp Gln Pro Tyr Ser Val Gln Ile
 1 5 10

<210> 782
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 782

Arg Phe Asp Tyr Trp Gln Pro Tyr Ser Asp Gln Thr
 1 5 10

<210> 783
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 783

Trp His Gln Phe Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 784
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 784

Glu Trp Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr Leu Leu
 1 5 10 15

Arg

<210> 785
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 785

Trp Glu Gln Asn Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Phe Ala
 1 5 10 15

Asp

<210> 786
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 786

Ser Asp Val Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Glu Met
 1 5 10 15

<210> 787
 <211> 17

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 787

Tyr Tyr Asp Gly Val Tyr Trp Gln Pro Tyr Ser Val Gln Val Met Pro
 1 5 10 15

Ala

<210> 788
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 788

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 789
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 789

Gln Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 790
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 790

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 791
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 791

Arg Ser Leu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 792
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 792

Thr Ile Ile Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 793
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 793

Trp Glu Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 794
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 794

Ser Tyr Asp Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 795
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 795

Ser Arg Ile Trp Cys Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 796
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 796

Glu Ile Met Phe Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 797

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 797

Asp Tyr Val Trp Gln Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 798

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 798

Met Asp Leu Leu Val Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 799

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 799

Gly Ser Lys Val Ile Leu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 800

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 800

Arg Gln Gly Ala Asn Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 801

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 801

Gly Gly Gly Asp Glu Pro Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 802

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 802

Ser Gln Leu Glu Arg Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 803

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 803

Glu Thr Trp Val Arg Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 804

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 804

Lys Lys Gly Ser Thr Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 805

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 805

Leu Gln Ala Arg Met Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 806

<211> 15

<212> PRT

<213> Artificial Sequence

```

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 806

Glu Pro Arg Ser Gln Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1          5          10          15

<210> 807
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 807

Val Lys Gln Lys Trp Arg Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1          5          10          15

<210> 808
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 808

Leu Arg Arg His Asp Val Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1          5          10          15

<210> 809
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 809

Arg Ser Thr Ala Ser Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1          5          10          15

<210> 810
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 810

Glu Ser Lys Glu Asp Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1          5          10          15

<210> 811
<211> 15

```

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 811

Glu Gly Leu Thr Met Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 812
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 812

Glu Gly Ser Arg Glu Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 813
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 813

Val Ile Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 814
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 814

Val Trp Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 815
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 815

Ala Ser Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 816
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 816

Phe Tyr Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 817
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 817

Glu Gly Trp Trp Val Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 818
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 818

Trp Gly Glu Trp Leu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 819
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 819

Asp Tyr Val Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 820
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 820

Ala His Thr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 821
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 821

Phe Ile Glu Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 822
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 822

Trp Leu Ala Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 823
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 823

Val Met Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 824
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 824

Glu Arg Met Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 825
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature

<222> (2, 3, 5)..(6)
 <223> Xaa = any amino acid

<400> 825

Asn Xaa Xaa Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 826
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 826

Trp Gly Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 827
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 827

Thr Leu Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 828
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 828

Val Trp Arg Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 829
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 829

Leu Leu Trp Thr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 830
 <211> 12

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(6)
 <223> Xaa = any amino acid

<400> 830

Ser Arg Ile Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 831
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 831

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 832
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(6)
 <223> Xaa = any amino acid

<400> 832

Trp Gly Tyr Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 833
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 833

Thr Ser Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 834
 <211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (5)..(6)
<223> Xaa = any amino acid

<400> 834

Val His Pro Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 835
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 835

Glu His Ser Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 836
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (1)..(2)
<223> Xaa = any amino acid

<400> 836

Xaa Xaa Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 837
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 837

Ala Gln Leu His Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 838
<211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 838

Trp Ala Asn Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 839
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 839

Ser Arg Leu Tyr Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 840
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 840

Gly Val Thr Phe Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 841
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 841

Ser Ile Val Trp Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 842
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 842

Ser Arg Asp Leu Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 843
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 843

His Trp Gly His Val Tyr Trp Gln Pro Tyr Ser Val Gln Asp Asp Leu
 1 5 10 15

Gly

<210> 844
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 844

Ser Trp His Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val Pro
 1 5 10 15

Glu

<210> 845
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 845

Trp Arg Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Pro Glu Ser
 1 5 10 15

Ala

<210> 846
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 846

Thr Trp Asp Ala Val Tyr Trp Gln Pro Tyr Ser Val Gln Lys Trp Leu
 1 5 10 15

Asp

<210> 847
 <211> 17
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <400> 847

Thr Pro Pro Trp Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Asp
 1 5 10 15

Pro

<210> 848
 <211> 17
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <400> 848

Tyr Trp Ser Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val His
 1 5 10 15

Ser

<210> 849
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <400> 849

Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu
 1 5 10

<210> 850
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <400> 850

Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 851
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 851

Glu Trp Ile Gln Pro Tyr Ala Thr Gly Leu
 1 5 10

<210> 852
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 852

Asn Trp Glu Gln Pro Tyr Ala Lys Pro Leu
 1 5 10

<210> 853
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 853

Ala Phe Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 854
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 854

Phe Leu Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 855
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 855

Val Cys Lys Gln Pro Tyr Leu Glu Trp Cys
 1 5 10

<210> 856
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 856

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 857
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 857

Gln Gly Trp Leu Thr Trp Gln Asp Ser Val Asp Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 858
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 858

Phe Ser Glu Ala Gly Tyr Thr Trp Pro Glu Asn Thr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 859
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 859

Thr Glu Ser Pro Gly Gly Leu Asp Trp Ala Lys Ile Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 860
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 860

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 861
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 861

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 862
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 862

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 863
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 863

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 864

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 864

Ser Trp Ser Glu Ala Phe Glu Gln Pro Arg Asn Leu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 865

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 865

Gln Tyr Ala Glu Pro Ser Ala Leu Asn Asp Trp Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 866

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 866

Asn Gly Asp Trp Ala Thr Ala Asp Trp Ser Asn Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 867

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 867

Thr His Asp Glu His Ile Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 868

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 868

Met Leu Glu Lys Thr Tyr Thr Thr Trp Thr Pro Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 869

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 869

Trp Ser Asp Pro Leu Thr Arg Asp Ala Asp Leu Tyr Trp Gln Pro Tyr
 1 5 10 15

Ala Leu Pro Leu
 20

<210> 870

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 870

Ser Asp Ala Phe Thr Thr Gln Asp Ser Gln Ala Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 871

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 871

Gly	Asp	Asp	Ala	Ala	Trp	Arg	Thr	Asp	Ser	Leu	Thr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
			20	

<210> 872

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 872

Ala	Ile	Ile	Arg	Gln	Leu	Tyr	Arg	Trp	Ser	Glu	Met	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
			20	

<210> 873

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 873

Glu	Asn	Thr	Tyr	Ser	Pro	Asn	Trp	Ala	Asp	Ser	Met	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
			20	

<210> 874

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 874

Met	Asn	Asp	Gln	Thr	Ser	Glu	Val	Ser	Thr	Phe	Pro	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
			20	

<210> 875
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 875

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 876
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 876

Gln Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 877
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 877

Glu Asn Pro Phe Thr Trp Gln Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 878
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 878

Val Thr Pro Phe Thr Trp Glu Asp Ser Asn Val Phe Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 879
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 879

Gln Ile Pro Phe Thr Trp Glu Gln Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 880
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 880

Gln Ala Pro Leu Thr Trp Gln Glu Ser Ala Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 881
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 881

Glu Pro Thr Phe Thr Trp Glu Glu Ser Lys Ala Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 882
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 882

A-527.ST25.txt

Thr Thr Thr Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20-

<210> 883
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 883

Glu Ser Pro Leu Thr Trp Glu Glu Ser Ser Ala Leu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 884
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 884

Glu Thr Pro Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 885
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 885

Glu Ala Thr Phe Thr Trp Ala Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 886
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 886

Glu Ala Leu Phe Thr Trp Lys Glu Ser Thr Ala Tyr Tyr Trp Gln Pro
1 - 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 887

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 887

Ser Thr Pro Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 888

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 888

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 889

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 889

Lys Ala Pro Phe Thr Trp Glu Glu Ser Gln Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 890

<211> 21

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 890

Ser Thr Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 891
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 891

Asp Ser Thr Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 892
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 892

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 893
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 893

Gln Thr Ala Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

A-527.ST25.txt

<210> 894
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 894

Glu Thr Leu Phe Thr Trp Glu Glu Ser Asn Ala Thr Tyr Trp Gln Pro
 1 5 10 15
 Tyr Ala Leu Pro Leu
 20

<210> 895
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 895

Val Ser Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15
 Tyr Ala Leu Pro Leu
 20

<210> 896
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 896

Gln Pro Tyr Ala Leu Pro Leu
 1 5

<210> 897
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a phosphotyrosyl residue

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is a 1-napthylalanyl residue

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is an azetidine residue

<400> 897

Xaa Xaa Pro Tyr Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10

<210> 898
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 898

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 899
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 899

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 900
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 900

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 901
 <211> 15

<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 901

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 902
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 902

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 903
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (13)..(13)
<223> Position 13, Xaa is an azetidine residue

<400> 903

Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Xaa Tyr Ala Leu
1 5 10 15

Pro Leu

<210> 904
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 904

Ala Asp Val Leu Tyr Trp Gln Pro Tyr Ala Pro Val Thr Leu Trp Val
 1 5 10 15

<210> 905

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST

<400> 905

Gly Asp Val Ala Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Thr Ser
 1 5 10 15

Leu

<210> 906

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 906

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu

<210> 907

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 7)..(8)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is prolyl or an azetidine residue

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is S, A, V or L

<400> 907

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 908

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (2, 7)..(8)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is prolyl or an azetidine residue

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is S, A, V or L

<400> 908

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 909

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is E, F, V, W or Y

<220>

<221> misc_feature

<222> (4)..(4)
 <223> Position 4, Xaa is prolyl or an azetidine residue

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is S, A, V or L

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Position 7, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Position 8, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 909

Xaa Xaa Gly Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 910
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is V, L, I, E, P, G, Y, M, T or D

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is Y, W or F

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Position 3, Xaa is E, F, V, W or Y

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa is prolyl or an azetidine residue;

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Position 7, Xaa is S, A, V or L

<220>
 <221> misc_feature

<222> (8)..(8)
 <223> Position 8, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E;

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> Position 9, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 910

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
 1 5

<210> 911
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 911

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 912
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Xaa = any amino acid

<400> 912

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 913
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 913

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 914
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 914

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 915
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 915

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 916
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 916

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10					15	

<210> 917
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is A, D, E, F, G, K, Q, S, T, V or Y

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is A, D, G, I, N, P, S, T, V or W

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Position 3, Xaa is A, D, G, L, N, P, S, T, W or Y

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Position 4, Xaa is A, D, E, F, L, N, R, V or Y

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa is A, D, E, Q, R, S or T

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is H, I, L, P, S, T or W

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Position 7, Xaa is A, E, F, K, N, Q, R, S or Y;

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Position 8, Xaa is D, E, F, Q, R, T or W

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> Position 9, Xaa is A, D, P, S, T or W

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is A, D, G, K, N, Q, S or T

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11, Xaa is A, E, L, P, S, T, V or Y

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Position 12, Xaa is V, L, I, E, P, G, Y, M, T or D

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> Position 13, Xaa is Y, W or F

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> Position 14, Xaa is E, F, V, W or Y

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> Position 16, Xaa is P or an azetidine residue;

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> Position 18, Xaa is S, A, V or L

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> Position 19, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> Position 20, Xaa is Q or P.

<400> 917

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa
 1 5 10 15

Tyr Xaa Xaa Xaa Leu
 20

<210> 918
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 918

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 919
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 919

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu

<210> 920
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 920

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 921
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 921

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 922
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 922

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 923
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 923

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 924

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 924

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 925

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 925

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 926

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 926

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 927

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 927

Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 928

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 928

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 929

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 929

Ala Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 930

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 930

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 931

<211> 11

<212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 931

Phe Glu Ala Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 932
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 932

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 933
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 933

Phe Glu Trp Thr Ala Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 934
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> IL-1 ANTAGONIST PEPTIDE

 <220>
 <221> misc_feature

<222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 934

Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 935
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 935

Phe Glu Trp Thr Pro Gly Ala Trp Gln Xaa Tyr
 1 5 10

<210> 936
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 936

Phe Glu Trp Thr Pro Gly Tyr Ala Gln Xaa Tyr
 1 5 10

<210> 937
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 937

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Ala
 1 5 10

<223> VIP-MIMETIC PEPTIDE

<400> 613

Lys Lys Tyr Leu Asn
1 5

<210> 614

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 614

Lys Lys Tyr Leu Asn Ser
1 5

<210> 615

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 615

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 616

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 616

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 617

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 617

Lys Lys Tyr Leu
1

<210> 618

<211> 5

<212> PRT

<213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 618

Lys Lys Tyr Asp Ala
 1 5

<210> 619
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 619

Ala Val Lys Lys Tyr Leu
 1 5

<210> 620
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 620

Asn Ser Ile Leu Asn
 1 5

<210> 621
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 621

Lys Lys Tyr Val
 1

<210> 622
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(3)
 <223> Position 3, Xaa is a lauric acid residue

<400> 622

Xaa Ile Xaa Asn
1

<210> 623
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 623

Asn Ser Tyr Leu Asn
1 5

<210> 624
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 624

Asn Ser Ile Tyr Asn
1 5

<210> 625
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is a norleucyl residue

<400> 625

Lys Lys Tyr Leu Xaa
1 5

<210> 626
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 626

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 627
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 627

Lys Lys Tyr Leu
1

<210> 628
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 628

Lys Lys Tyr Asp Ala
1 5

<210> 629
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 629

Ala Val Lys Lys Tyr Leu
1 5

<210> 630
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 630

Asn Ser Ile Leu Asn
1 5

<210> 631
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE

<400> 631

Lys Lys Tyr Val
1

<210> 938
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 938

Phe Glu Trp Thr Gly Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 939
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 5, D amino acid residue
Position 10, Xaa is an azetidine residue

<400> 939

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 940
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (5)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 940

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 941
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa is a pipecolic acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 941

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 942
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is an aminoisobutyric acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 942

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 943
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is a sarcosine residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 943

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
1 5 10

<210> 944 -
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is a sarcosine residue

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 944

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 945
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 945

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr
1 5 10

<210> 946
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<220>
<221> misc_feature
<222> (5)..(5)

<223> Position 5, D amino acid residue

<400> 946

Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 947

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 947

Phe Glu Trp Thr Val Pro Tyr Trp Gln Xaa Tyr
1 5 10

<210> 948

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 948

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 949

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 949

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 950
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = 1-naphthylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 950

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 951
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, xaa is an azetidine residue

<400> 951

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 952
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 952.

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 953
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 953

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 954
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 954

Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 955
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<220>
<221> misc_feature
<222> (10)..(10)
<223> Position 10, Xaa is an azetidine residue

<400> 955

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
Page 263

1

5

10

<210> 956
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = naphthylalanine

<400> 956

Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met
 1 5 10

<210> 957
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = naphthylalanine

<400> 957

Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr
 1 5 10

<210> 958
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = naphthylalanine

<400> 958

Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser
 1 5 10

<210> 959
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 959

Asn	Met	Val	Tyr	Xaa	Gln	Pro	Tyr	Ser	Ile	Gln	Thr
1				5						10	

<210> 960

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 960

Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln
1			5					

<210> 961

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = naphthylalanine

<400> 961

Val	Tyr	Xaa	Gln	Pro	Tyr	Ser	Val	Gln
1			5					

<210> 962

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa is an azetidine residue

<400> 962

Thr	Phe	Val	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 963

<211> 11

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11, Xaa = p-benzoyl-L-phenylalanine

<400> 963

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
 1 5 10

<210> 964
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11, Xaa = p-benzoyl-L-phenylalanine.

<400> 964

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
 1 5 10

<210> 965
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (8)..(10)
 <223> Position 8, Xaa = p-benzoyl-L-phenylalanine
 Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 965

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
 1 5 10

<210> 966
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated Phe

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> Position 8, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 966

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
 1 5 10

<210> 967
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Position 7, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 967

Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
 1 5 10

<210> 968
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated Phe

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> Position 7, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 968

Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
 1 5 10

<210> 969
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated Phe

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Position 3, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 969

Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 970
 <211> 11

<212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated Phe

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Position 3, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 970

Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 971
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 971

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 972
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 972

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 973
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 973

Val Tyr Trp Gln Pro Tyr Ser Val Gln
 1 5

<210> 974
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 974

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 975
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Position 5, Xaa = naphthylalanine

<400> 975

Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 976
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 976

Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 977

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 977

Arg Leu Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 978

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 978

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 979

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = D or Y

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = D or S

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa = S, T or A

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = S or W

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = S or Y

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa = N, S, K, H or W

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa = F or L

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = D, N, S or L

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = L, I, Q, M or A.

<400> 979

Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 980

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 980

Asp Asn Ser Ser Trp Tyr Asp Ser Phe Leu Leu
1 5 10

<210> 981

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 981

Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala
1 5 10

<210> 982

<211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 982

Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu
 1 5 10

<210> 983
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 983

Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp
 1 5 10 15

Cys

<210> 984
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 984

Thr Ser Glu Tyr Asp Asn Thr Thr Trp Tyr Glu Lys Phe Leu Ala Ser
 1 5 10 15

Gln

<210> 985
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 985

Ser Gln Ile Pro Asp Asn Thr Ala Trp Tyr Gln Ser Phe Leu Leu His
 1 5 10 15

Gly

<210> 986
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 986

Ser Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 987
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 987

Glu Gln Ile Tyr Asp Asn Thr Ala Trp Tyr Asp His Phe Leu Leu Ser
1 5 10 15

Tyr

<210> 988
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 988

Thr Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 989
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 989

Thr Tyr Thr Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Met Ser
1 5 10 15

Tyr

<210> 990
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 990

Thr Met Thr Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser
 1 5 10 15

Tyr

<210> 991
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 991

Thr Ile Asp Asn Thr Ala Trp Tyr Ala Asn Leu Val Gln Thr Tyr Pro
 1 5 10 15

Gln

<210> 992
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 992

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Ala Gln Tyr Pro
 1 5 10 15

Asp

<210> 993
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 993

His Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr Tyr Thr
 1 5 10 15

Pro

<210> 994
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 994

Ser Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser Tyr Lys
 1 5 10 15

Ala

<210> 995
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 995

Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn
 1 5 10 15

Ala

<210> 996
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 996

Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn
 1 5 10 15

Thr

<210> 997
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 997

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Asn His Asn
 1 5 10 15

Leu

<210> 998
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 998

His Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Gln Gln Gly Trp
 1 5 10 15

His

<210> 999
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 999

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 1000
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 1000

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 1001
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1001

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 - 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1002

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa = naphthylalanine

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3; Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an azetidine residue.

<400> 1002

Xaa Xaa Xaa Gln Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 1003

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1003

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1004
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1004

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 1005
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 1005

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Ser
 1 5 10 15

Asp

<210> 1006
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1006

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 1007
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature

<222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1007

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1008
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 is acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1008

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1009
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 1 is acetylated Phe
 Position 10, Xaa = azetidine

<400> 1009

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1010
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1010

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1011

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1011

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1012

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1012

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1013

<211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 is acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1013

Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 1014
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1014

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 1015
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1015

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 1016
 <211> 15
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1016

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10						15

<210> 1017

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1017

Thr	Ala	Asn	Val	Ser	Ser	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
			20	

<210> 1018

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<400> 1018

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5				10		

<210> 1019

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 is acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1019

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1020
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 is acetylated Phe

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 1020

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1021
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1 is acetylated Phe

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, D amino acid residue

<220>
 <221> misc_feature
 <222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1021

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1022

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1022

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1023

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1023

Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 1024 -
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1024

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
 1 5 10 15

Tyr Lys Gly Gly
 20

<210> 1025
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1025

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly
 20

<210> 1026
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1026

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Leu Gly Gly
 20

<210> 1027
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<400> 1027

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu -

<210> 1028
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> MMP INHIBITOR

<400> 1028

Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 1029
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<400> 1029

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly Gly
20

<210> 1030
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC PEPTIDE

<400> 1030

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 1031
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> VEGF- ANTAGONIST

<400> 1031

A-527.ST25.txt

Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

Thr Glu Ala Gln
20

<210> 1032
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC

<220>
<221> misc_feature
<222> (1)..(1)
<223> Fc domain attached at Position 1 of the N-terminus

<400> 1032

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15

Ala Arg Ala

<210> 1033
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> TPO-MIMETIC

<220>
<221> misc_feature
<222> (19)..(19)
<223> Fc domain attached at Position 19 of the C-terminus

<400> 1033

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly

<210> 1034
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> EPO-MIMETIC

<220>
<221> misc_feature
<222> (25)..(25)

<223> Fc domain attached at Position 25 of the C-terminus

<400> 1034

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly
20 25

<210> 1035

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1035

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 1036

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1036

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 1037

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1037

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 1038

<211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1038

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
 1 5 10 15

Arg Pro Ser Pro Lys Ala
 20

<210> 1039
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1039

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1040
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1040

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10

<210> 1041
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<400> 1041

Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1042
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature
 <222> (1)..(1)
 <223> Xaa (Pos1) can be any one of the 20 L-amino acids; except Xaa (Pos1) may/may not be Y and Xaa (Pos1) may be any non-naturally occurring aromatic acid analog when Xaa (Pos1) is Y.

<220>
 <221> misc_feature
 <222> (2)..(8)
 <223> Xaa (Pos2, 8) can be any one of the 20 L-amino acids

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Xaa (Pos3) can be C, A, a-amino-γ-bromobutyric acid or Hoc;

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Xaa (Pos4) can be R, H, L or W

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa (Pos5) can be M, F or I

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Xaa is any amino acid

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Xaa (Pos11) can be D, E, I, L or V

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Xaa (Pos12) can be C, A, a-amino-γ-bromobutyric acid or Hoc provided that either Xaa (Pos3, 12) is C or Hoc.

<400> 1042

Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
 1 5 10

<210> 1043
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<220>
 <221> misc_feature
 <222> (3)..(4)
 <223> Xaa = any amino acid

<400> 1043

Asp Leu Xaa Xaa Leu
1 - 5

<210> 1044

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1044

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu
1 5 10

<210> 1045

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1045

Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu
1 5 10 15

Gly His Arg Pro
20

<210> 1046

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR

<220>

<221> misc_feature

<222> (20)..(20)

<223> Fc domain attached at Position 20 of the C-terminus

<400> 1046

Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly
1 5 10 15

Gly Gly Gly Gly
20

<210> 1047
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus

<400> 1047

Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
 1 5 10 15

Ala Leu Pro Leu
 20

<210> 1048
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> Fc domain attached at Position 20 of the C-terminus

<400> 1048

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly
 1 5 10 15

Gly Gly Gly Gly
 20

<210> 1049
 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus

<400> 1049

Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met Trp
 1 5 10 15

Glu Trp Glu Cys Phe Glu Arg Leu
20

<210> 1050
 <211> 24
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> VEGF-ANTAGONIST
 <220>
 <221> misc_feature
 <222> (24)..(24)
 <223> Fc domain attached at Position 24 of the C-terminus

<400> 1050

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu Gly Gly Gly Gly Gly
20

<210> 1051
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> MMP INHIBITOR
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Fc domain attached at Position 1 of the N-terminus

<400> 1051

Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10 15

<210> 1052
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> MMP INHIBITOR
 <220>
 <221> misc_feature
 <222> (15)..(15)
 <223> Fc domain attached at Position 15 of the C-terminus

<400> 1052

Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly
1 5 10 15

<210> 1053
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 1053

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr
 1 5 10

<210> 1054
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 1054

Arg Thr Asp Leu Asp Ser Leu Arg Thr
 1 5

<210> 1055
 <211> 757
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> FC-TNF-ALPHA INHIBITORS

<220>
 <221> CDS
 <222> (4)..(747)
 <223>

<400> 1055
 cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48
 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 15
 1 5 10
 ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96
 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 30
 20 25
 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 45
 35 40
 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 60
 50 55
 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 75
 65 70
 acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 95
 80 85 90

A-527.ST25.txt

```

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc      336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
      100      105      110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca      384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
      115      120      125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag      432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
      130      135      140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc      480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
      145      150      155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg      528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
      160      165      170      175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc      576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
      180      185      190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc      624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
      195      200      205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc      672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
      210      215      220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt gac ttc ctg ccg cac tac      720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr
      225      230      235

aaa aac acc tct ctg ggt cac cgt ccg taatggatcc      757
Lys Asn Thr Ser Leu Gly His Arg Pro
      240      245

```

<210> 1056

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TNF-ALPA INHIBITORS

<400> 1056

```

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1      5      10

```

```

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
      20      25      30

```

```

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
      35      40      45

```

```

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50      55      60

```

A-527.ST25.txt

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys
225 230 235 240

Asn Thr Ser Leu Gly His Arg Pro
245

<210> 1057
<211> 761
<212> DNA
<213> Artificial Sequence

<220>
<223> TNF-ALPHA INHIBITOR-Fc

<220>
<221> CDS
<222> (4)..(747)
<223>

<400> 1057
cat atg gac ttc ctg ccg cac tac aaa aac acc tct ctg ggt cac cgt 48
Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg
1 5 10 15

ccg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
Page 297

A-527.ST25.txt

Pro	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro		
				20					25					30			
gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	144	
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys		
			35-					40					45				
ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	192	
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val		
		50					55				60						
gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	240	
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr		
	65					70					75						
gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	288	
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu		
80					85				90						95		
cag	tac	aac	agc	acg	tac	cat	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	336	
Gln	Tyr	Asn	Ser	Thr	Tyr	Asp	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His		
				100					105					110			
cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	384	
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys		
			115					120					125				
gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	432	
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln		
		130					135					140					
ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	480	
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu		
	145					150					155						
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	528	
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro		
160					165					170					175		
agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	576	
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn		
				180					185					190			
tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	624	
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu		
			195					200					205				
tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	672	
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val		
		210				215					220						
ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	720	
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln		
	225					230					235						
aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc	gcgg						761	
Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys									
240					245												

<210> 1058
 <211> 248
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> TNF-ALPHA INHIBITOR-Fc

<400> 1058

```

Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro
1      5      10      15

Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
20      25      30

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
35      40      45

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
50      55      60

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65      70      75      80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85      90      95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100     105     110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115     120     125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130     135     140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145     150     155     160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165     170     175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180     185     190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
195     200     205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
210     215     220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225     230     235     240

Ser Leu Ser Leu Ser Pro Gly Lys
245

```

<210> 1059

<211> 763

<212> DNA
 <213> Artificial Sequence

<220>
 <223> FC-IL-1 ANTAGONIST

<220>
 <221> CDS
 <222> (4)..(747)
 <223>

```

<400> 1059
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc      48
  Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
  1          5          10          15

ctg ggg gga ccg tca gtc ttc ctc ttc cca aaa ccc aag gac acc      96
  Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr
          20          25          30

ctc atg atc tcc ccg acc cct gag gtc aca tgc gtg gtg gtg gac gtg    144
  Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
          35          40          45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg    192
  Ser His Glu Asp Pro Glu Val Lys Phe Asn Val Val Asp Gly Val
          50          55          60

gag gtg cat aat gcc aag aca aag ccg ccg gag tac aac agc      240
  Glu Val His Asn Ala Lys Thr Lys Pro Arg Gln Gln Tyr Asn Ser
          65          70          75

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ccg    288
  Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
          80          85          90          95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc    336
  Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
          100          105          110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca    384
  Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
          115          120          125

cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag aac cag    432
  Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
          130          135          140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc    480
  Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
          145          150          155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg    528
  Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
          160          165          170          175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc    576
  Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
          180          185          190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc    624
  Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
          195          200          205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc    672
  Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
          210          215          220

```


A-527.ST25.txt

ctg tct ccg ggt aaa ggt gga ggt ggt ggt ttc gaa tgg acc ccg ggt 720
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly
 225 230 235

tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag 763
 Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 240 245

<210> 1060
 <211> 248
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FC-IL-1 ANTAGONIST

<400> 1060

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

A-527.ST25.txt

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 - 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr
225 230 235 240

Trp Gln Pro Tyr Ala Leu Pro Leu
245

<210> 1061
<211> 757
<212> DNA
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST-FC

<220>
<221> CDS
<222> (4)..(747)
<223>

<400> 1061
cat atg ttc gaa tgg acc ccg ggt tac tgg cag ccg tac gct ctg ccg 48
Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro 15
1 5 10
ctg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro 20 25 30
gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 35 40 45
ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 50 55 60
gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 240
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 65 70 75
gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 288
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 80 85 90 95
cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac 336
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 100 105 110
cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 384
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 115 120 125
gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 432
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 130 135 140
ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 480
Page 302

A-527.ST25.txt

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 145 150 155

acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 528
 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 160 - 165 170 175

agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 576
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 180 185 190

tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 624
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 195 200 205

tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 672
 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 210 215 220

ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 720
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 225 230 235

aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc 757
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 240 245

<210> 1062
 <211> 248
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST-FC

<400> 1062

Met Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 20 25 30

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 35 40 45

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 50 55 60

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
 245

<210> 1063
 <211> 773
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-VEGF ANTAGONIST

<220>
 <221> CDS
 <222> (4)..(759)
 <223>

<400> 1063
 cat atg gac aaa act cac aca tgt cca ccg tgc cca gca cct gaa ctc 48
 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 1 5 10 15
 ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag gac acc 96
 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 20 25 30
 ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 35 40 45
 agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192
 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 50 55 60
 gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 65 70 75

A-527.ST25.txt

```

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg      288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
80                               85                               90                               95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc      336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
100                            105                            110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca      384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
115                            120                            125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag      432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
130                            135                            140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc      480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
145                            150                            155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg      528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
160                            165                            170                            175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc      576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
180                            185                            190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc      624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
195                            200                            205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc      672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
210                            215                            220

ctg tct ccg ggt aaa ggt ggt ggt ggt ggt gtt gaa ccg aac tgt gac      720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp
225                            230                            235

atc cat gtt atg tgg gaa tgg gaa tgt ttt gaa cgt ctg taactcgagg      769
Ile His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
240                            245                            250

atcc                                                                    773

```

<210> 1064
 <211> 252
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-VEGF ANTAGONIST

<400> 1064

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

```

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50                      55                      60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65                      70                      75                      80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
                      85                      90                      95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
                      100                      105                      110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
                      115                      120                      125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
                      130                      135                      140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145                      150                      155                      160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
                      165                      170                      175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
                      180                      185                      190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
                      195                      200                      205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210                      215                      220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile
225                      230                      235                      240

His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
                      245                      250

```

```

<210> 1065
<211> 773
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> VEGF ANTAGONIST-Fc

```

```

<220>
<221> CDS
<222> (4)..(759)
<223>

```

A-527.ST25.txt

<400> 1065

cat	atg	gtt	gaa	ccg	aac	tgt	gac	atc	cat	gtt	atg	tgg	gaa	tgg	gaa	48
Met	Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu		
1				5					10					15		
tgt	ttt	gaa	cgt	ctg	ggg	ggg	ggg	ggg	ggg	gac	aaa	act	cac	aca	tgt	96
Cys	Phe	Glu	Arg	Leu	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	
				20					25					30		
cca	ccg	tgc	cca	gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	144
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	
			35					40					45			
ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	192
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	
		50					55					60				
gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	240
Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	
	65					70					75					
ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	288
Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	
80					85					90					95	
ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	336
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	
				100					105					110		
acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	384
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	
			115					120					125			
gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	432
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	
		130					135						140			
gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	480
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	
	145					150					155					
cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	528
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	
160					165					170					175	
ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	576
Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	
				180					185					190		
ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	624
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	
			195					200					205			
tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	672
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	
		210					215					220				
cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	720
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	
	225					230					235					
cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggg	aaa	taactc	gagg		769
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys				
240					245					250						
atcc																773

<210> 1066
 <211> 252
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> VEGF ANTAGONIST-Fc

<400> 1066

Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys
 1 5 10 15

Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro
 20 25 30

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
 35 40 45

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 50 55 60

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 65 70 75 80

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 85 90 95

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 100 105 110

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 115 120 125

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 130 135 140

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 145 150 155 160

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 165 170 175

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 180 185 190

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 195 200 205

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 210 215 220

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 225 230 235 240

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 1067
<211> 748
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc MMP INHIBITOR

<220>
<221> CDS
<222> (4)..(732)
<223>

<400> 1067
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
1 5 10 15
ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
20 25 30
ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
35 40 45
agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
50 55 60
gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
65 70 75
acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
80 85 90 95
aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
100 105 110
ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
115 120 125
cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
130 135 140
gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
145 150 155
gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
160 165 170 175
cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
180 185 190

A-527.ST25.txt

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
195 200 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
210 215 220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt tgc acc acc cac tgg ggt 720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Cys Thr Thr His Trp Gly
225 230 235

ttc acc ctg tgc taatggatcc ctcgag 748
Phe Thr Leu Cys
240

<210> 1068
<211> 243
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc MMP INHIBITOR

<400> 1068

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

A-527.ST25.txt

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe
225 230 235 240

Thr Leu Cys

<210> 1069
<211> 763
<212> DNA
<213> Artificial Sequence

<220>
<223> MMP INHIBITOR-Fc

<220>
<221> CDS
<222> (4)..(753)
<223>

<400> 1069
cat atg tgc acc acc cac tgg ggt ttc acc ctg tgc ggt gga ggc ggt 48
Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly 15
1 5 10

ggg gac aaa ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct 96
Gly Asp Lys Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro 30
20 25

tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc 144
Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 40 45

cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca 192
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 50 55 60

tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac 240
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 65 70 75

tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg 288
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 80 85 90 95

gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc 336
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 100 105 110

ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc 384

A-527.ST25.txt

Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser		
			115					120					125				
aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa		432
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys		
		130	-				135					140					
ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat		480
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp		
		145					150					155					
gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc		528
Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe		
160					165					170					175		
tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag		576
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu		
				180					185						190		
aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc		624
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe		
			195					200					205				
ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg		672
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly		
		210					215					220					
aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac		720
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr		
		225				230					235						
acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggg	aaa	taatggatcc						763
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys							
240					245					250							

<210> 1070
 <211> 250
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> MMP INHIBITOR-Fc

<400> 1070

Met	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu	Cys	Gly	Gly	Gly	Gly	Gly		
1				5					10					15			
Asp	Lys	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys		
		20						25					30				
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro		
		35				40						45					
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys		
		50				55					60						
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp		
65					70				75					80			
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu		
			85						90					95			

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 100 105 110
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 115 120 125
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 130 135 140
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 145 150 155 160
 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 165 170 175
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 180 185 190
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 195 200 205
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 210 215 220
 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 225 230 235 240
 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 1071
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 1071

Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
 1 5 10

<210> 1072
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INTEGRIN-BINDING PEPTIDE

<400> 1072

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
 1 5 10

<210> 1073
 <211> 8
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1073

Cys Leu Ser Gly Ser Leu Ser Cys
 1 5

<210> 1074
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1074

Asn Gly Arg Ala His Ala
 1 5

<210> 1075
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1075

Cys Asn Gly Arg Cys
 1 5

<210> 1076
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1076

Cys Asp Cys Arg Gly Asp Cys Phe Cys
 1 5

<210> 1077
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> INTEGRIN-BINDING PEPTIDE
 <400> 1077

Cys Gly Ser Leu Val Arg Cys
1 5

<210> 1078
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 1078

Arg Thr Asp Leu Asp Ser Leu Arg
1 5

<210> 1079
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 1079

Gly Asp Leu Asp Leu Leu Lys Leu Arg Leu Thr Leu
1 5 10

<210> 1080
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 1080

Gly Asp Leu His Ser Leu Arg Gln Leu Leu Ser Arg
1 5 10

<210> 1081
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 1081

Arg Asp Asp Leu His Met Leu Arg Leu Gln Leu Trp
1 5 10

<210> 1082
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE

<400> 1082

Ser Ser Asp Leu His Ala Leu Lys Lys Arg Tyr Gly
 1 5 10

<210> 1083

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1083

Arg Gly Asp Leu Lys Gln Leu Ser Glu Leu Thr Trp
 1 5 10

<210> 1084

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1084

Arg Gly Asp Leu Ala Ala Leu Ser Ala Pro Pro Val
 1 5 10

<210> 1085

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1085

Arg Gly Trp Val Glu Ile Cys Val Ala Asp Asp Asn Gly Met Cys Val
 1 5 10 15

Thr Glu Ala Gln
 20

<210> 1086

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1086

Gly Trp Asp Glu Cys Asp Val Ala Arg Met Trp Glu Trp Glu Cys Phe
 1 5 10 15

Ala Gly Val

<210> 1087
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<400> 1087

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
 1 5 10 15

<210> 1088
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<400> 1088

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
 1 5 10 15

<210> 1089
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<400> 1089

Gly Gly Asn Glu Cys Asp Ile Ala Arg Met Trp Glu Trp Glu Cys Phe
 1 5 10 15

Glu Arg Leu

<210> 1090
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VEGF-ANTAGONIST

<400> 1090

Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
 1 5 10 15

<210> 1091
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa = any amino acid

<400> 1091

Cys Leu Arg Ser Gly Xaa Gly Cys
1 5

<210> 1092

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (2, 3, 8)..(9)

<223> Xaa = any amino acid.

<400> 1092

Cys Xaa Xaa His Trp Gly Phe Xaa Xaa Cys
1 5 10

<210> 1093

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (2)..(4)

<223> Xaa = any amino acid

<400> 1093

Cys Xaa Pro Xaa Cys
1 5

<210> 1094

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1094

Cys Arg Arg His Trp Gly Phe Glu Phe Cys
1 5 10

<210> 1095
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220> -
 <223> MMP INHIBITOR

<400> 1095

Ser Thr Thr His Trp Gly Phe Thr Leu Ser
 1 5 10

<210> 1096
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CTLA4-MIMETIC

<400> 1096

Cys Ser Leu His Trp Gly Phe Trp Trp Cys
 1 5 10

<210> 1097
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CARBOHYDRATE (GD1 ALPHA) MIMETIC

<400> 1097

Trp His Trp Arg His Arg Ile Pro Leu Gln Leu Ala Ala Gly Arg
 1 5 10 15

<210> 1098
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1098

Leu Lys Thr Pro Arg Val
 1 5

<210> 1099
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1099

Asn Thr Leu Lys Thr Pro Arg Val
 1 5

<210> 1100
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1100

Asn	Thr	Leu	Lys	Thr	Pro	Arg	Val	Gly	Gly	Cys
1				5					10	

<210> 1101
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1101

Lys	Asp	Lys	Ala	Thr	Phe
1				5	

<210> 1102
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1102

Lys	Asp	Lys	Ala	Thr	Phe	Gly	Cys	His	Asp
1				5					10

<210> 1103
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1103

Lys	Asp	Lys	Ala	Thr	Phe	Gly	Cys	His	Asp	Gly	Cys
1				5					10		

<210> 1104
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> BETA2GPI AB BINDING

<400> 1104

Thr Leu Arg Val Tyr Lys
1 5

<210> 1105
<211> 9 -
<212> PRT
<213> Artificial Sequence

<220>
<223> BETA2GPI AB BINDING

<400> 1105

Ala Thr Leu Arg Val Tyr Lys Gly Gly
1 5

<210> 1106
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> BETA2GPI AB BINDING

<400> 1106

Cys Ala Thr Leu Arg Val Tyr Lys Gly Gly
1 5 10

<210> 1107
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> MEMBRANE-TRANSPORTING

<400> 1107

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 1108
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> MEMBRANE-TRANSPORTING

<400> 1108

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly
1 5 10

<210> 1109
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> MEMBRANE-TRANSPORTING

<400> 1109

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
 1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
 20 25

<210> 1110

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1110

gttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg 57

<210> 1111

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1111

cagacgttca aaacattccc attcccacat aacatggatg tcacagttcg gttcaac 57

<210> 1112

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TNA-ALPHA INHIBITORS

<400> 1112

ccgcggatcc attacggacg gtgacccaga gaggtgtttt tgtagtgagg caggaagtca 60

ccaccacctc cacctttacc c 81

<210> 1113

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<220>

<221> CDS

<222> (1)..(57)

<223>

<400> 1113

gtt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa tgt ttt 48

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
 1 5 10 15

gaa cgt ctg 57

Glu Arg Leu

<210> 1114
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc VEGF ANTAGONIST

<400> 1114

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
 1 5 10 15

Glu Arg Leu

<210> 1115
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc MMP INHIBITOR

<400> 1115
 ccgcggatcc attagcacag ggtgaaaccc cagtgggtgg tgcaaccacc acctccacct 60
 ttaccc 66

<210> 1116
 <211> 63
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> MMP INHIBITOR Fc

<400> 1116
 gaataacata tgtgcaccac ccactgggggt ttcaccctgt gcggtggagg cgggtggggac 60
 aaa 63

<210> 1117
 <211> 81
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TNF-ALPHA INHIBITOR Fc

<400> 1117
 gaataacata tggacttcct gccgcactac aaaaacacct ctctgggtca ccgtccgggt 60
 ggaggcgggtg gggacaaaac t 81

<210> 1118
 <211> 81
 <212> DNA
 <213> Artificial Sequence

```

<220>
<223>  Fc IL-1 ANTAGONIST

<400>  1118
ccgcggatcc attacagcgg cagagcgtac ggctgccagt aaccggggt ccattcgaaa      60
ccaccacctc cacctttacc c                                              81

<210>  1119
<211>  81
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IL-1 ANTAGONIST Fc

<400>  1119
gaataacata tgttcgaatg gaccccggt tactggcagc cgtacgctct gccgctgggt      60
ggaggcgggtg gggacaaaac t                                              81

<210>  1120
<211>  48
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fc VEGF ANTAGONIST

<400>  1120
atttgattct agaaggagga ataacatatg gacaaaactc acacatgt                  48

<210>  1121
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fc VEGF ANTAGONIST

<400>  1121
gtcacagttc ggttcaacac caccaccacc acctttaccc ggagacaggg a              51

<210>  1122
<211>  54
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fc VEGF ANTAGONIST

<400>  1122
tcctgtctc cgggtaaagg tgggtgggt ggtggtgaac cgaactgtga catc            54

<210>  1123
<211>  39
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Fc VEGF ANTAGONIST

```


<400> 1123
ccgcggatcc tcgagttaca gacgttcaaa acattccca 39

<210> 1124
<211> 48 -
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF ANTAGONIST Fc

<400> 1124
atttgattct agaaggagga ataacatatg gttgaaccga actgtgac 48

<210> 1125
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF ANTAGONIST Fc

<220>
<221> misc_feature
<222> (2)..(2)
<223> Position 2, Xaa is L-lys, D-lys, or an ornithyl residue

<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3, Xaa is L-tyr, D-tyr, phe, trp, or a p-aminophenylalanine residue

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is a hydrophobic aliphatic amino acid residue

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, optional attachment to leu, norleucyl, D-ala, Asn-Ser, asn-ser-ile, asn-ser-tyr, asn-ser-ile-leu, asn-ser-tyr-leu, or asn-ser-tyr-leu-asn

<400> 1125
acatgtgtga gttttgtcac caccaccacc acccagacgt tcaaacatt c 51

<210> 1126
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF ANTAGONIST Fc

<400> 1126
gaatgttttg aacgtctggg tgggtggtggg ggtgacaaaa ctcacacatg t 51

<210> 1127

<211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> VEGF ANTAGONIST Fc

<400> 1127
 ccgcggatcc tcgagttatt tacccggaga cagggagag

39

<210> 1128
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Butoxycarbonyl group attached to the amino terminus.

<220>
 <221> misc_feature
 <222> (2, 5, 24 and)..(27)
 <223> Tert-butyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (7, 13, 29 and)..(35)
 <223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (8 and)..(30)
 <223> Trityl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (9 and)..(31)
 <223> Butoxycarbonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (36)..(36)
 <223> Methoxy resin attached to the carboxyl terminus.

<400> 1128

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

A-527.ST25.txt

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 1129
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Butoxycarbonyl group attached to the amino terminus.

<220>
 <221> misc_feature
 <222> (2, 5, 24 and)..(27)
 <223> Tert-butyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (7, 12, 29 and)..(35)
 <223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (8 and)..(30)
 <223> Trityl group attached to the sidechain

<220>
 <221> misc_feature
 <222> (9 and)..(31)
 <223> Butoxycarbonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (36)..(36)
 <223> Methoxy resin attached to the carboxyl terminus.

<400> 1129

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala

35

```

<210> 1130
<211> 36
<212> PRT -
<213> Artificial Sequence

<220>
<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
<221> misc_feature
<222> (1)..(1)
<223> Butoxycarbonyl group attached to the amino terminus.

<220>
<221> misc_feature
<222> (2, 5, 24 and)..(27)
<223> Tert-butyl group attached to the sidechain.

<220>
<221> misc_feature
<222> (7, 13, 29 and)..(35)
<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached
to the sidechain.

<220>
<221> misc_feature
<222> (8 and)..(30)
<223> Trityl group attached to the sidechain.

<220>
<221> misc_feature
<222> (9 and)..(31)
<223> Butoxycarbonyl group attached to the sidechain.

<220>
<221> misc_feature
<222> (18)..(18)
<223> Bromoacetyl group attached to the sidechain.

<220>
<221> misc_feature
<222> (36)..(36)
<223> Methoxy resin attached to the carboxyl terminus.

<400> 1130
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15
Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30
Ala Ala Arg Ala
35

```

<210> 1131
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> Bromoacetyl group attached to the sidechain.

<400> 1131

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 1132
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>
 <221> misc_feature
 <222> (2, 5, 24 and)..(27)
 <223> Tert-butyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (7, 13, 29 and)..(35)
 <223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (8, 18 and)..(30)
 <223> Trityl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (9 and)..(31)
 <223> Butoxycarbonyl group attached to the sidechain.

<220>
 <221> misc_feature
 <222> (36)..(36)
 <223> Methoxy resin attached to the carboxyl terminus.

<400> 1132

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1				5				10						15	

Gly	Cys	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu
		20						25					30		

Ala	Ala	Arg	Ala
		35	

<210> 1133

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<400> 1133

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1				5				10						15	

Gly	Cys	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu
		20						25					30		

Ala	Ala	Arg	Ala
		35	